CA2133411A1 - Gene therapy using targeted viral vectors - Google Patents
Gene therapy using targeted viral vectorsInfo
- Publication number
- CA2133411A1 CA2133411A1 CA002133411A CA2133411A CA2133411A1 CA 2133411 A1 CA2133411 A1 CA 2133411A1 CA 002133411 A CA002133411 A CA 002133411A CA 2133411 A CA2133411 A CA 2133411A CA 2133411 A1 CA2133411 A1 CA 2133411A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- envelope
- protein
- hybrid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013603 viral vector Substances 0.000 title description 17
- 238000001415 gene therapy Methods 0.000 title description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 167
- 241000700605 Viruses Species 0.000 claims abstract description 148
- 239000003446 ligand Substances 0.000 claims abstract description 45
- 230000004927 fusion Effects 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 239000012634 fragment Substances 0.000 claims description 61
- 101710091045 Envelope protein Proteins 0.000 claims description 58
- 101710188315 Protein X Proteins 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 54
- 230000008685 targeting Effects 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 230000003612 virological effect Effects 0.000 claims description 27
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 238000004806 packaging method and process Methods 0.000 claims description 23
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 238000010348 incorporation Methods 0.000 claims description 15
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 12
- 230000034303 cell budding Effects 0.000 claims description 10
- 241000712907 Retroviridae Species 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241000700586 Herpesviridae Species 0.000 claims description 6
- 238000006384 oligomerization reaction Methods 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 4
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 abstract description 141
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 29
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000007429 general method Methods 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 102100034349 Integrase Human genes 0.000 description 55
- 239000013612 plasmid Substances 0.000 description 37
- 239000013598 vector Substances 0.000 description 25
- 230000002494 anti-cea effect Effects 0.000 description 23
- 210000004779 membrane envelope Anatomy 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 230000001177 retroviral effect Effects 0.000 description 17
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 16
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 15
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 241001430294 unidentified retrovirus Species 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 108700004025 env Genes Proteins 0.000 description 10
- 101150030339 env gene Proteins 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 108020004491 Antisense DNA Proteins 0.000 description 8
- 239000003816 antisense DNA Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 108010078428 env Gene Products Proteins 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 241000557626 Corvus corax Species 0.000 description 6
- 102100034353 Integrase Human genes 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 108010015780 Viral Core Proteins Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 208000028782 Hereditary disease Diseases 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000005265 lung cell Anatomy 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000024556 Mendelian disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- -1 e.g. Proteins 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241000712892 Arenaviridae Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 101710189136 Envelope fusion protein Proteins 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000701377 Iridoviridae Species 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- AHEWZZJEDQVLOP-UHFFFAOYSA-N monobromobimane Chemical compound BrCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O AHEWZZJEDQVLOP-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108700025685 HIV Enhancer Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
- C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A general method for delivering genes to specific target cells in vivo is described. Enveloped viruses are genetically engineered to infect specific target cells by replacing the cell surface receptor recognition domain of viral envelope proteins with ligands that direct the binding and fusion of these viruses to specific cell surface molecules.
Description
WO93/20221 . 913 3 g 11 PCT/US93/02957 J'~ . .
GENE THERAPY USTNG TARGETED VIRAL VECTORS
Backaround of the Invention The invention relates to gene therapy methods.
Gene therapy is an approach to treating a broad range of diseases by delivering therapeutic genes directly into the human body. Diseases that can potentially be cured by gene therapy include 1) diseases associated with the aging population such as cancer, 10 heart disease, Alzheimer' 8 disease, high blood pressure, atherosclerosis and arthritis; 2) viral infectious diseases such as acquired immune deficiency syndrome (AIDS) and herpes; and 3) inherited diseases such as diabetes, hemophilia, cystic fibrosis, and muscular 15 dystrophy.
Current methods of delivery of new genetic information into cells in vitro include cell fusion, chromosome-mediated insertion, microcell-mediated gene transfer, liposome DNA carriers, spheroplast fusion, DNA-20 mediated gene transfer, microinjection, infection withrecombinant RNA viruses, and infection with recombinant DNA viruses (Martin, J.C., 1984, Mol. C~ll Biochem. 59:3-10). These techniques are not generally applicable, howevsr, for use in animals or humans because of low 25 efficiency, instability of introduced genes, introduction of extraneous or undesirable genetic information, and lack of target specificity.
In one particular example, a favored approach for human gene therapy involves the transplantation of 30 genetically-altQred cells into patients (Rosenberg, et al., 1988, New Eng J Med~cine 323:570-578). This approach requires the surgical removal of cells from each patient to isolate target cells from nontarget cells.
Genes are introduced into these cells via viral vectors 35 or other maans, followed by transplantation of the W093/20221 ~13 3 ~1 1 i i; . ' .~ PCT/US93/02g57 genetically-altered cells back into the patient.
Although this approach is useful for purposes such as enzyme replacement therapy (for example, for transplantation into a patient of cells that secrete a 5 hormone that diseased cells can no longer secrete), transplantation strategies are less likely to be suitable for treating diseases such as cystic fibrosis or cancer, where the diseased cells themselves must be corrected.
Other problems commonly encountered with this approach lO include technical problems, including inefficient transduction of stem cells, low expression of the transgene, and growth of cells in tissue culture which may select for cells that are predisposed to cancer.
Finally, inappropriate expression of transplanted genes ~5 in nontarget oells may actually be harmful to patients.
An alternative approach to gene therapy involves the direct delivery of genes to target tissue in situ.
Two methods for in s~tu delivery of genes have been developed: biolistic transfer and double balloon 20 catheterization. Biolistic transfer of genes involves shooting DNA-~oated platinum or gold micropro~ectiles directly into target tissue. Biolistic transfer has been successful in the transient expression of genes in the ear, skin and surgically-exposed liver of live mice ~Johnston, S.A., l990, Natur~ ~46:776-777; Williams, R.S., et al., l99l, Proc Na~l Acad Sci USA 88:2726-2730).
Double balloon catheterization transduces genes into cells within a defined arterial wall segment. In this approach a double balloon catheter is inserted into an 30 artery until the end of the catheter is located within the target area. Inflation of two balloons at the end of the catheter creates an enclosed space into which retrovirus or DNA-loaded liposomes are infused. This ~ method has been successful in the transient expression of `~ 35 ~-galactosidase genes within a defined segment of the wo g3,2022. 2 1 3 3 4 1 1 ; ~ , PCT/US93/02gS7 ileofemoral artery of pigs (Nabel E.G., et al., 19~0, Science 249:1285-1288). Both biolistic transfer and double balloon catheterization however, althouqh locally specific, may be nonspecific in the individual cells that 5 they transduce within the target area, creating a problem of inappropriate gene regulation if the transgene is expressed in nontarget cells. Moreover, neither biolistic transfer nor double balloon catheterization have been shown to be effective for the treatment of - 10 tissue occupying large volumes such as lungs, muscles, tumors, or cells of the systemic circulation since the majority of the cells would be inaccessible for in situ gene transfer.
A third approach to gene therapy is the delivery 15 of genes to cells in vivo. This approach involves the introduction of viral vectors directly into patients by in~ection, spray or other means. Different species of viruses are engineered to deliver genes to the cells that the viruses normally infect. Adenovirus, for example, 20 which normally infects lung cells, has been developed as a vector to target genes to lung cells (Rosen~ield, et al., 1992, Cell 68 143-155). Most viral vectors, however, are single purpose vectors since they can only deliver genes to certain cells. Because the target cell 25 specificity of viral vectors i8 re~tricted to the normal tropisms of the viruses, viral vectors are generally limited in that they either infect too broad a range of cell types, or they do not infect certain types of cells at all.
Liposomes have been designed to deliver genes or drugs to specific target cells ~n v~vo. By chemically con~ugating antibodies or ligands to liposomes, liposomes have been targeted to specific cells. With this method, antisense env RNA has been delivered to human 35 immunodeficiency virus (HIV)-infected lymphocytes using W093/20221 ~ 1334 ~ PCT/US93/02ff~
anti-CD3-conjugated liposomes (Renneisen, K ., et al., 1990, J Biol Chem 265:16337-16342); chloramphenicol transacetylase (CAT) genes have been delivered to H2Kk positive lymphomas in H2Kk-negative nude mice using anti-5 H2Kk-conjugated liposomes (Wang, C. et al., 1987, Proc Natl Acad Sci USA 84:7851-7855); and xanthine guanine phosphoribosyltransferase (XGPRT) genes have been delivered to immunoglobulin-coated cells using ~ staphy}ococcus protein A-conjugated liposomes (Machy P., ;~ 10 et al., 1988, Proc Natl Acad sci USA 85:8027-8031). The major drawback to this technology can be the expense of mass producing ligand-con~ugated liposomes.
Wu et al. report a method to target naked DNA to specific cells. Asialoglycoprotein-DNA complexes are 15 targeted to hepatocytes expressing the asialoglycoprotein ;receptor (Wu G.Y., et al., 1991, Biotherapy 3:87-95) .
Similar to the problem encountered with immunotoxins, however, this ~trategy generally limits delivery of DNA
to cells expressing receptors that are capable of DNA-: `~
20 internalization.
Antisense DNA technology is a method ror inhibiting the expression of specific genes with complementary DNA (Moffat, 1991, Science ~:510-511).
Although antisense DNA is specific in the genes that it 25 affects, it is nonæpecific in the types of cells that it gets into. This can create problems ~n vivo because it is desirable that endogenous genes in normal cells remain unaffected by antisense DNA (e.g., protooncogenes).
Moreover, the cost of manufacturing and administering 30 antisense DNA may be high because the phosphate moieties of antisense DNA must be chemically mod~fied to allow passage through tbe plasma membrane, a process which entails expensive organic chemistry. Millimolar concentrations of antisense DNA are required to be 35 effective, posing problems of potential toxicity in vivo.
WO93/20221 ~ 3 34fll~ PCT/US93/02g5 Human gene therapy is therefore limited by.the available technology for gene delivery. Transplantation strategies, which require surgery, limit gene therapy to an expensive service industry for a small number of 5 diseases. Targeting of genes in s~tu through local transduction is generally not precise enough. Viral vectors limit the delivery of genes ~n vivo to cells that the viruses normally infect. Liposome technologies may be infeasible because of the expense of production.
lO Simple ligand-DNA complexes will not introduce genes into cells unless the receptors, against which the ligan~s are direct~d, internalize. Acoordingly, currently available gene delivery systems impose severe limitations on the spectrum of diseases that can be treated by gene therapy.
Summary of the Invention The invention features a method for expressing a nucleic acid of intere~t in a heterologous host cell.
The method involves providing a virus whose genome comprises i) the nucleic acid of ~nterest, and ii) a ; 20 hybrid envelope gene. The hybrid gene encodes an ;~ envelope fragment ~oined to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding of its normal host cell but does facilitate efficient incorporation of the virus into a mature viral 25 particle, and whereby the targeting ligand facilitates targeting ~nd binding of the mature viral particle to the surface of the heterologous host cell. The method also involves administering the virus so as to permit viral infection of the cell.
By "efficient incorporation", is meant that the hybrid envelope protein ~g incorporated into a mature viral particle at least 25% a8 frequently as the corresponding wild-type envelope protein is incorporated into a mature viral particle.
,_,, !
WO93/20221 rcT/usg3/o29s7 ~1334~11; `
In another aspect the invention features a virus, the genome of which encodes a hybrid envelope protein, wherein the hybrid protein comprises an envelope fragment joined in frame to a targeting ligand, whereby the s envelope fragment does not facilitate recognition or binding of its normal host cell but which does facilitate efficient incorporation of the hybrid envelope protein into a mature viral particle and whereby the non-viral protein facilitates targeting and binding of the mature 10 viral particle to the surface of a cell not normally infected by the virus.
In a third aspect the invention features a method for~delivering a nucleic acid of interest to a heterologous host cell. The method involves providing a 15 virus that~comprises i) the nucleic acid of interest, and ~-~ ii) a hybrid envelope gene, the hybrid gene encoding an envelope fragment joined to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding to its normal host cell but does facilitate 20 efficient incorporation of the virus into a m~ture viral particle, and whereby the targeting ligand faailitates targeting and binding of the mature viral particle to the surface of the heterologous host cell. The method also involves administering the virus so as to permit viral 25 infection of the cell.
In various preferred embodiments the virus is an enveloped virus, preferably a Herpesviridae, a Paramyxoviridae, or a Retroviridae, most preferably a Moloney murine leukemia virus, or the viru~ may also 30 preferably be a Hepadnaviridae, a Poxviridae, or an Iridoviridae. Similarly tbe virus may be a Togaviridae, a Flaviviridae, a Coronaviridae, a Rhabodoviridae, a Filoviridae, an Orthomyxoviridae, a BunyaviridaQ, or an Arenaviridae, or any other, yet unclassified, enveloped 35 virus.
~"~
.
W093/20221 ~i 3 3 ~ ; PCT/US93/02gS7 In other various preferred embodiments the nucleic acid of interest may include, without limitation, an antisense oncogene; a tumor suppressor gene, e.g., a gene encoding p53, or a gene encoding retinoblastoma protein 5 Rb; a toxin gene, e.g., a diphtheria toxin gene; or a gene encoding a cytokine, e.g., a tumor necrosis factor, or an interferon. The nucleic acid of interest may be either DNA or RNA, e.g., antisense DNA, or antisense RNA, or a nucleic acid encoding an antisense RNA. The nucleic lO acid of interest may also be a gene invoking intracellular immunity, or a nucleic acid therapeutic for an inherited disease, e.g., an insulin gene, or a cystic fibrosis transmembrane regulator gene. A "gene that invokes intracellular immunity" is a gene that confers a lS dominant negati~e re~istant phenotype to the cell it is in.~thereby protecting the cell against an invading aqent.
The heterologous host cell may be a cell that has acquired mutations that re~ult in a disea~e ~tate, 20 preferably a cancer cell, e.g., a colon cancer cell. The ` heterologous host cell may be a cell infected ~ith a second virus, e.g., a human immunodeficiency virus (HIV), a cell infected with an organism, or an infectious agent such as a bacterium or parasite. The infectiouæ agent 25 may be either unicellular or multicellular. The heterologous host cell may also be a cell affected by a hereditary disease, e.g., a pancreatic beta cell, or a ~` lung cell.
The targeting ligand, in additional various 30 preferred embodiments, may include a protein, preferably a hormone, or an immunoglobulin, more preferably an anti-tumor associated antigen-specific immunoglobulin, most preferably an anti-carcinoembryonic antigen-specific ` immunoglobulin, or an anti-HIVgpl20 antigen-specific 35 immùnoglobulin. The targeting ligand may also be a WO93/20221 Z 1 3 3 ~ PCT/US93/02957 carbohydrate, or a lipid. The hybrid envelope fragment may consist of a receptor binding domain, an oligomerization domain, a transmembrane domain, a virus budding domain, sorting signals, a signal sequence, and 5 preferably a fusion domain. In some cases the fusion activity of the envelope fragment may be performed by a second protein. The second protein would therefore direct fusion of the virus with the membrane of the targeted cell.
The mode of admini~tration may include, but is not limited to, l) direct injection of the purified virus; or
GENE THERAPY USTNG TARGETED VIRAL VECTORS
Backaround of the Invention The invention relates to gene therapy methods.
Gene therapy is an approach to treating a broad range of diseases by delivering therapeutic genes directly into the human body. Diseases that can potentially be cured by gene therapy include 1) diseases associated with the aging population such as cancer, 10 heart disease, Alzheimer' 8 disease, high blood pressure, atherosclerosis and arthritis; 2) viral infectious diseases such as acquired immune deficiency syndrome (AIDS) and herpes; and 3) inherited diseases such as diabetes, hemophilia, cystic fibrosis, and muscular 15 dystrophy.
Current methods of delivery of new genetic information into cells in vitro include cell fusion, chromosome-mediated insertion, microcell-mediated gene transfer, liposome DNA carriers, spheroplast fusion, DNA-20 mediated gene transfer, microinjection, infection withrecombinant RNA viruses, and infection with recombinant DNA viruses (Martin, J.C., 1984, Mol. C~ll Biochem. 59:3-10). These techniques are not generally applicable, howevsr, for use in animals or humans because of low 25 efficiency, instability of introduced genes, introduction of extraneous or undesirable genetic information, and lack of target specificity.
In one particular example, a favored approach for human gene therapy involves the transplantation of 30 genetically-altQred cells into patients (Rosenberg, et al., 1988, New Eng J Med~cine 323:570-578). This approach requires the surgical removal of cells from each patient to isolate target cells from nontarget cells.
Genes are introduced into these cells via viral vectors 35 or other maans, followed by transplantation of the W093/20221 ~13 3 ~1 1 i i; . ' .~ PCT/US93/02g57 genetically-altered cells back into the patient.
Although this approach is useful for purposes such as enzyme replacement therapy (for example, for transplantation into a patient of cells that secrete a 5 hormone that diseased cells can no longer secrete), transplantation strategies are less likely to be suitable for treating diseases such as cystic fibrosis or cancer, where the diseased cells themselves must be corrected.
Other problems commonly encountered with this approach lO include technical problems, including inefficient transduction of stem cells, low expression of the transgene, and growth of cells in tissue culture which may select for cells that are predisposed to cancer.
Finally, inappropriate expression of transplanted genes ~5 in nontarget oells may actually be harmful to patients.
An alternative approach to gene therapy involves the direct delivery of genes to target tissue in situ.
Two methods for in s~tu delivery of genes have been developed: biolistic transfer and double balloon 20 catheterization. Biolistic transfer of genes involves shooting DNA-~oated platinum or gold micropro~ectiles directly into target tissue. Biolistic transfer has been successful in the transient expression of genes in the ear, skin and surgically-exposed liver of live mice ~Johnston, S.A., l990, Natur~ ~46:776-777; Williams, R.S., et al., l99l, Proc Na~l Acad Sci USA 88:2726-2730).
Double balloon catheterization transduces genes into cells within a defined arterial wall segment. In this approach a double balloon catheter is inserted into an 30 artery until the end of the catheter is located within the target area. Inflation of two balloons at the end of the catheter creates an enclosed space into which retrovirus or DNA-loaded liposomes are infused. This ~ method has been successful in the transient expression of `~ 35 ~-galactosidase genes within a defined segment of the wo g3,2022. 2 1 3 3 4 1 1 ; ~ , PCT/US93/02gS7 ileofemoral artery of pigs (Nabel E.G., et al., 19~0, Science 249:1285-1288). Both biolistic transfer and double balloon catheterization however, althouqh locally specific, may be nonspecific in the individual cells that 5 they transduce within the target area, creating a problem of inappropriate gene regulation if the transgene is expressed in nontarget cells. Moreover, neither biolistic transfer nor double balloon catheterization have been shown to be effective for the treatment of - 10 tissue occupying large volumes such as lungs, muscles, tumors, or cells of the systemic circulation since the majority of the cells would be inaccessible for in situ gene transfer.
A third approach to gene therapy is the delivery 15 of genes to cells in vivo. This approach involves the introduction of viral vectors directly into patients by in~ection, spray or other means. Different species of viruses are engineered to deliver genes to the cells that the viruses normally infect. Adenovirus, for example, 20 which normally infects lung cells, has been developed as a vector to target genes to lung cells (Rosen~ield, et al., 1992, Cell 68 143-155). Most viral vectors, however, are single purpose vectors since they can only deliver genes to certain cells. Because the target cell 25 specificity of viral vectors i8 re~tricted to the normal tropisms of the viruses, viral vectors are generally limited in that they either infect too broad a range of cell types, or they do not infect certain types of cells at all.
Liposomes have been designed to deliver genes or drugs to specific target cells ~n v~vo. By chemically con~ugating antibodies or ligands to liposomes, liposomes have been targeted to specific cells. With this method, antisense env RNA has been delivered to human 35 immunodeficiency virus (HIV)-infected lymphocytes using W093/20221 ~ 1334 ~ PCT/US93/02ff~
anti-CD3-conjugated liposomes (Renneisen, K ., et al., 1990, J Biol Chem 265:16337-16342); chloramphenicol transacetylase (CAT) genes have been delivered to H2Kk positive lymphomas in H2Kk-negative nude mice using anti-5 H2Kk-conjugated liposomes (Wang, C. et al., 1987, Proc Natl Acad Sci USA 84:7851-7855); and xanthine guanine phosphoribosyltransferase (XGPRT) genes have been delivered to immunoglobulin-coated cells using ~ staphy}ococcus protein A-conjugated liposomes (Machy P., ;~ 10 et al., 1988, Proc Natl Acad sci USA 85:8027-8031). The major drawback to this technology can be the expense of mass producing ligand-con~ugated liposomes.
Wu et al. report a method to target naked DNA to specific cells. Asialoglycoprotein-DNA complexes are 15 targeted to hepatocytes expressing the asialoglycoprotein ;receptor (Wu G.Y., et al., 1991, Biotherapy 3:87-95) .
Similar to the problem encountered with immunotoxins, however, this ~trategy generally limits delivery of DNA
to cells expressing receptors that are capable of DNA-: `~
20 internalization.
Antisense DNA technology is a method ror inhibiting the expression of specific genes with complementary DNA (Moffat, 1991, Science ~:510-511).
Although antisense DNA is specific in the genes that it 25 affects, it is nonæpecific in the types of cells that it gets into. This can create problems ~n vivo because it is desirable that endogenous genes in normal cells remain unaffected by antisense DNA (e.g., protooncogenes).
Moreover, the cost of manufacturing and administering 30 antisense DNA may be high because the phosphate moieties of antisense DNA must be chemically mod~fied to allow passage through tbe plasma membrane, a process which entails expensive organic chemistry. Millimolar concentrations of antisense DNA are required to be 35 effective, posing problems of potential toxicity in vivo.
WO93/20221 ~ 3 34fll~ PCT/US93/02g5 Human gene therapy is therefore limited by.the available technology for gene delivery. Transplantation strategies, which require surgery, limit gene therapy to an expensive service industry for a small number of 5 diseases. Targeting of genes in s~tu through local transduction is generally not precise enough. Viral vectors limit the delivery of genes ~n vivo to cells that the viruses normally infect. Liposome technologies may be infeasible because of the expense of production.
lO Simple ligand-DNA complexes will not introduce genes into cells unless the receptors, against which the ligan~s are direct~d, internalize. Acoordingly, currently available gene delivery systems impose severe limitations on the spectrum of diseases that can be treated by gene therapy.
Summary of the Invention The invention features a method for expressing a nucleic acid of intere~t in a heterologous host cell.
The method involves providing a virus whose genome comprises i) the nucleic acid of ~nterest, and ii) a ; 20 hybrid envelope gene. The hybrid gene encodes an ;~ envelope fragment ~oined to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding of its normal host cell but does facilitate efficient incorporation of the virus into a mature viral 25 particle, and whereby the targeting ligand facilitates targeting ~nd binding of the mature viral particle to the surface of the heterologous host cell. The method also involves administering the virus so as to permit viral infection of the cell.
By "efficient incorporation", is meant that the hybrid envelope protein ~g incorporated into a mature viral particle at least 25% a8 frequently as the corresponding wild-type envelope protein is incorporated into a mature viral particle.
,_,, !
WO93/20221 rcT/usg3/o29s7 ~1334~11; `
In another aspect the invention features a virus, the genome of which encodes a hybrid envelope protein, wherein the hybrid protein comprises an envelope fragment joined in frame to a targeting ligand, whereby the s envelope fragment does not facilitate recognition or binding of its normal host cell but which does facilitate efficient incorporation of the hybrid envelope protein into a mature viral particle and whereby the non-viral protein facilitates targeting and binding of the mature 10 viral particle to the surface of a cell not normally infected by the virus.
In a third aspect the invention features a method for~delivering a nucleic acid of interest to a heterologous host cell. The method involves providing a 15 virus that~comprises i) the nucleic acid of interest, and ~-~ ii) a hybrid envelope gene, the hybrid gene encoding an envelope fragment joined to a targeting ligand, whereby the envelope fragment does not facilitate recognition or binding to its normal host cell but does facilitate 20 efficient incorporation of the virus into a m~ture viral particle, and whereby the targeting ligand faailitates targeting and binding of the mature viral particle to the surface of the heterologous host cell. The method also involves administering the virus so as to permit viral 25 infection of the cell.
In various preferred embodiments the virus is an enveloped virus, preferably a Herpesviridae, a Paramyxoviridae, or a Retroviridae, most preferably a Moloney murine leukemia virus, or the viru~ may also 30 preferably be a Hepadnaviridae, a Poxviridae, or an Iridoviridae. Similarly tbe virus may be a Togaviridae, a Flaviviridae, a Coronaviridae, a Rhabodoviridae, a Filoviridae, an Orthomyxoviridae, a BunyaviridaQ, or an Arenaviridae, or any other, yet unclassified, enveloped 35 virus.
~"~
.
W093/20221 ~i 3 3 ~ ; PCT/US93/02gS7 In other various preferred embodiments the nucleic acid of interest may include, without limitation, an antisense oncogene; a tumor suppressor gene, e.g., a gene encoding p53, or a gene encoding retinoblastoma protein 5 Rb; a toxin gene, e.g., a diphtheria toxin gene; or a gene encoding a cytokine, e.g., a tumor necrosis factor, or an interferon. The nucleic acid of interest may be either DNA or RNA, e.g., antisense DNA, or antisense RNA, or a nucleic acid encoding an antisense RNA. The nucleic lO acid of interest may also be a gene invoking intracellular immunity, or a nucleic acid therapeutic for an inherited disease, e.g., an insulin gene, or a cystic fibrosis transmembrane regulator gene. A "gene that invokes intracellular immunity" is a gene that confers a lS dominant negati~e re~istant phenotype to the cell it is in.~thereby protecting the cell against an invading aqent.
The heterologous host cell may be a cell that has acquired mutations that re~ult in a disea~e ~tate, 20 preferably a cancer cell, e.g., a colon cancer cell. The ` heterologous host cell may be a cell infected ~ith a second virus, e.g., a human immunodeficiency virus (HIV), a cell infected with an organism, or an infectious agent such as a bacterium or parasite. The infectiouæ agent 25 may be either unicellular or multicellular. The heterologous host cell may also be a cell affected by a hereditary disease, e.g., a pancreatic beta cell, or a ~` lung cell.
The targeting ligand, in additional various 30 preferred embodiments, may include a protein, preferably a hormone, or an immunoglobulin, more preferably an anti-tumor associated antigen-specific immunoglobulin, most preferably an anti-carcinoembryonic antigen-specific ` immunoglobulin, or an anti-HIVgpl20 antigen-specific 35 immùnoglobulin. The targeting ligand may also be a WO93/20221 Z 1 3 3 ~ PCT/US93/02957 carbohydrate, or a lipid. The hybrid envelope fragment may consist of a receptor binding domain, an oligomerization domain, a transmembrane domain, a virus budding domain, sorting signals, a signal sequence, and 5 preferably a fusion domain. In some cases the fusion activity of the envelope fragment may be performed by a second protein. The second protein would therefore direct fusion of the virus with the membrane of the targeted cell.
The mode of admini~tration may include, but is not limited to, l) direct injection of the purified virus; or
2) implanting a container enclosing the virus into a patient. When the virus is administered inside a container, the virus is preferably inside a packaging ~lS cell. A "packaging cell" is a cell that supplies viral ;~proteins necessary for production of viral vectors. By "container" is meant a virus permeable enclosure containing virus, or containing packaging cells with virus therein.
"Normal host cell" as used herein, is a cell type commonly infected by the naturally occurring ~irus. In contrast, the term "heterologous host cell" or a "targeted cell", as used herein, refers to a cell that is' recognized as a function of the targeting ligand portion 25 of the hybrid envelope protein, but i8 not recognized as a function of the envelope portion of the hybrid envelope protein. By "targeting ligand" is meant a molecule that has binding affinity for a moleculQ on tbe surface of a desired targeted cell. A "hybrid envelope protein", as 30 used herein, is a protein that includes a portion of a viral envelope protein ~or a biologically active analog thereof) covalently linked to a targeting ligand. For example, by a "hybrid immunoglobulin-env protein" is meant a portion of an immunoglobulin covalently linked to 35 a portion of an envelope protein. A "hybrid envelope W O 93/20221 ~ 1 3 3 4 1 1 " , `, PC~r/US93/02957 gene" i~ a nucleic acid that provides genetic instructions for a hybrid envelope protein. By "hybrid anti-carcinoembryonic antigen-specific immunoglobulin" is meant a hybrid immunoglobulin-env protein that 5 specifically binds to a carcinoembryonic antigen.
The term "fragment", as applied to an envelope protein fragment, includes some but not all of the envelope protein. A fragment will ordinarily be at least about about 20 amino acids, typically at least about 30 10 amino acids, usually at least about 40 contiguous amino acids, preferably at least about 50 amino acids, and most preferably at least about 60 to 80 or more contiguous amino acids in length. Fragments of an envelope protein can be generated by methods known to those skilled in the 15 art (e.g., those described herein~.
A biologically active fragment of a viral anvelope protein is one that possesses at least one of the following activities: a) it can bind to a cell membrane if given the appropriate targeting ligand; b) it can 20 enable fusion with a cell membrane; or c) it can enable incorporation of proteins into a mature viral-particle.
These three biological activities can be performed by the same envelope protein fragment, or by two separate envelope protein fragments. As stated above, the 25 envelope fragments of this invention do not facilitate recognition or binding of the virus' normal host cell.
This is accomplished by either destroying the activity of the normal receptor binding region by mutation, or by physically deleting it. A new recombinant receptor-30 binding region i8 added in its place. The ability of acandidate fragment to exhibit a biological activity of a viral envelope protein can be assessed by methods known to those skilled in the art.
The envelope fragment may include the amino acid 35 sequence of a naturally-ocurring viral envelope or may be WO93/20221 '~1 3 3 4 1 I PCT/US93/02957 a biologically-active analog thereo~. The biologLca activity of an envelope analog is assessed using the methods described herein for testing envelope fragments for activity.
S Applicants have provided an efficient and reliable means for ~pecifically delivering therapeutic genes or antisense nucleic acids to particular animal, plant or .
human cell types, or to cells of infectious agents.
Their method facilitates treatments for mutagenically 10 acquired, infectious, or inherited diseases, e.g., by either 1~ antagonizing the effect of an existing cellular ~; gene; 2) complementing the defect of an existing cellular gene; 3) destroying the target cells through the introduction of new genetic material; or 4) changing the 15 phenotype of the target cells through the introduction of ` new g-netic material. To specifically target cells for delivery, a hybrid envelope protein (e.g., an envelope-antibody or envelope-ligand hybrid) is utilized which directs specific interaction with a particular target 20 host cell. The viru~es itself, through its efficient internalization mechanisms, facilitates efficient uptake of the therapeutic gene. Such viral vectors are uniquely ~; adapted to deliver genes, RNA, or drugs to cell surface proteins that do not normally internalize.
Another advantage of this invention is that it overcomes the problem of gene regulation encountered with other methods of gene therapy. ~enetically-altered cells must not only synthesize the gene products at the right location, at the right time, and in the right amounts, 30 but must also be regul~ted in the ~me manner as the indigenous tis~ue. That is, the transduced cells must also have all the proper signal transduction mechanisms to respond to extracellular signals. This may be a problem in gene therapy for diabetes, for example, where 35 transplanting fibroblasts with insulin genes can be ' , W O 93/20221 ~ -~ 3 3 4 1 I PC~r~US93/02957 ineffective or even harmful. As fibroblasts do not contain the same receptors and signal transduction machinery as pancreatic beta cells, the insulin genes may be expressed differently. Targeting genes to the right 5 cells insures that the genes will be properly regulated.
In an additional aspect of the invention, a selection scheme is devised for creation of hybrid envelope protein-containing viruses. This strategy will be feasible for env proteins fused with immunoglobulins 10 or with any ligand that recognizes specific receptors on cells.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
I5 Detailed Description The drawings will first briefly be described.
Drawinas FIG. 1 is a representation of a scheme for constructing retroviral vector pLNCX*.
FIG. 2 is a representation of a scheme for constructing plasmid LNCenvpA.
FIG. 3 is a representation of a scheme for constructing plasmid LNC~nv.
FIG. 4 is a representation of a scheme for 25 constructing plasmid pUC Star-Sig.
FIG. 5 is a representation of a scheme for constructing plasmid LNC-Sig.
FIG. 6 is a representation of a scheme for ` constructing plasmid LNC-ant~CEA.
FIG. 7 is a representation of plasmids used in the construction of targeted viruses.
FIG. 8 is a representation of a strategy for generating targeted retroviruses involving construction of hybrid immunoglobulin-env genes in vitro.
2~33~1, , j WO93/20221 ~ ~, PCT/US93/02957 FIG. 9 is a representation of a strategy ~or generating targeted retroviruses involving generation of pooled virus constructions.
FIG. lo is a representation of a strategy for s generating targeted retroviruses involving selection and characterization of targeted virus.
FIG. 11 is a representation of a plasmid containing a targeted retroviral vector.
FIG. 12 is a representation of a scheme for 10 constructing plasmid pU~ Star-antiCEA.
FIG. 13 is a representation of an alternative scheme for constructing plasmid LNC-antiCEA.
What follows is a procedure for the delivery of genes to target cells using targeted viral vectors. To 15 create and target a virus, the receptor recognition domain of the viral envelope protein is replaced with a ligand directed against a specific cell surface receptor.
The hybsid envelope protein is incorporated into the ~ viral envelope during the budding proce~s, producing a - ~ 20 hybrid virus ~n v~vo. Upon infection of a host, the ~ . ~
hybrid virus specifically recognizes its target cell and resultant fusion with that cell facilitates internalization (into the target cell) of viral genes, including the therapeutic gene(s) which are engineered 25 into the viral genome. Such internalization can be extremely important; for example, immunotoxins, although efficient at delivering toxin molecules to target cells, are often clinically ineffective since the cell surface molecules to which they are targQted do not ~nternalize, 30 and internalization is re~uired for entry of the toxin molecules into the cells ~Waldmann, T.A., 1991, Sc~ence 252: 1657-1662). Targeted viruses circumvent this requirement for receptor internalization since the virus itself contains the necessary cell fusion machinery (Gilbert, J.M., et al., 1990, J Virol 64: 5106-5113;
~, WO93/20221 ~ 3 3 9 1 1 PCT/US93/02957 Roizman, B. et al., 1990, in BN Fields, et al., eds.
Viroloov, Raven Press, Ltd. New York).
General Reauirements for Taraeted Viruses In general targeted viruses are constructed by 5 replacing the receptor recognition domain of the viral envelope protein with a ligand directed against a specific cell surface receptor. The ligand can be, without limitation, an immunoglobulin (e.g., FAb, dAb, Fd, or Fc), a hormone, or any other synthetic or natural 10 protein that can direct the binding of the targeted viruses to a cell surface molecule. The ligand is biologically incorporated into the viral envelope by genetic fusion with that portion of the normal viral envelope protein involved in viral assembly and budding.
15 The envelope portion of the hybrid protein consists of an envelope fragment (or analog thereof) that is sufficient to direct efficient incorporation of the envelope hybrid :`
protein into the viral envelope. Preferably, the ;~ envelope hybrid protein no longer directs an interaction 20 between the virus and ~ts normal host cell.
It has been demonstrated that changing~the receptor specificity of the envelope protein of a virus changes the virus's tropism. `For example, vesicular stomatitis virus (VSV) pseudotypes that have their virus 25 envelope replaced with that of a retrovirus acquire the ability to infect retrovirus infectable cells (Schnitzer, T.J., et al., 1977, J Gen Virol 23:449-454; Zavada. J., et al., 1~72, J Gen Virol ~:183-191), indicating that species specific protein-protein interactions between a 30 virus core protein and an envelope protein are not critical for v~rus fusion and penetration at least in these cases~ Moreover, previous experiments have also indicated that virus envelopes can tolerate changes in ~ length or conformation introduced into the envelope -~ 35 protein, e.g., by a conjugated ligand. For example, ' ;:
WO93t20221 ~ ~ 334t~ ` PCT/US93/02957 Gitman et al. have shown that Sendai virus envelo~es reconstituted with viral envelope glycoproteins, chemically cross-linked to anti-erythrocyte antibodies acquire the ability to bind to erythrocytes that had been 5 stripped of the normal virus receptor. Similarly, Sendai ; virus envelopes reconstituted with envelope proteins, chemically cross-linked to insulin molecules, were able to bind to receptor-stripped erythrocytes expressing the insulin receptor. In both cases, envelope binding but lO not fusion occurred with the receptor-stripped erythrocytes. Fusion between the conjugated envelopes and erythrocytes occurred, however, when the conjugated~
e m elopes were coreconstituted with t~e normal viral hemagglutinin/neuraminidase and fusion proteins (Gitman, 15 A.G., et al., 1985, Biochem 24:2762-2768).
, ` Preferably, the targeted virus contains l) a viral envelope derived from a host cellular membrane; 2) a transmembrane hybrid envelope protein that directs the binding and penetration of the virus to specific target 20 cells; 3) a transmembrane envelope protein that directs he fusion of the targeted virus with the cel~ular membrane of the targeted cell for viral penetration (e.g., the targeting protein itself or another envelope protein); 4) viral core proteins; 5) a foreign gene(s) of 25 interest; and 6) all necessary viral and genetic components for penetration and expression of genes contained in the viral genome. The transmembrane hybrid envelope protein consists of l) determinants that enable the hybrid protein to become processed and incorporated 30 into viral envelopes; 2) det~rminants that enable fus~on of the viral envelope with the targeted cellular membrane; these are essential for penetration of the targeted virus; 3) a ligand determinant that enables the targeted virus to recognize and bind to specific 35 receptors on target cells. The viral genome may also ~:~
W093/20221 ~ 1 3 3 4 1 1 PCT/US93/02957 include bacterial selectable markers (e.g., ampicillin resistance) andlor a mammalian cell selectable marker (e.g., neomycin resistance).
The transmembrane hybrid protein is constructed S genetically by ~plicing the cell surface receptor binding domain of a ligand gene to a portion of the viral envelope protein gene. The transmembrane hybrid protein must retain those portions of the envelope protein that direct the effioient post-translational processing, lO sorting and incorporation of the protein into the viral envelope.
The following domains must be considered in constructing the hybrid ligand-envelope protein:
l. The receptor bindina domain ;~ 15 The receptor binding domain is that portion of the envelope protein that recognizes and binds to cell ~urface receptors. In hybrid envelope proteins, this ; portion of the envelope protein is replaced with ligand sequences. The receptor binding domain of retrovirus 20 envelope proteins h~s bQen localized to the SU subunit (Coffin, J.M., l990, in BN Fields, et al., ed~. Virology, Raven Press, Ltd., New York). Since the SU protein of retroviruses is coded for 5' to the transmembrane pro~ein, replacement of the amino-terminal sequences of 25 the envelope protein with ligand sequences poses no pro~lem for the creation of a functional hybrid ligand-envelope protein.
2. Proteolytic cleavaae site The envelope protein of retroviruses is 30 synthesized as a polyprotein which is later proteolytically cleaved to form SU and TM heterodimers.
In construction of the hybrid ligand-envelope protein, the proteolytic cleavage site should b~ eliminated. Tbe proteolytic cleavage site sbould be eliminated either by 3S deletion or by site directed mutagenesis. Perez and W093/20221 ~3341~` ~ i PCT/US93/02957 Hunter have demonstrated that elimination of the proteolvtic cleavage site does not block transport or surface expression of Rous sarcoma virus envelope proteins (Perez, L.G., et al., 1987, J Virol ~1:1609-5 1614).
"Normal host cell" as used herein, is a cell type commonly infected by the naturally occurring ~irus. In contrast, the term "heterologous host cell" or a "targeted cell", as used herein, refers to a cell that is' recognized as a function of the targeting ligand portion 25 of the hybrid envelope protein, but i8 not recognized as a function of the envelope portion of the hybrid envelope protein. By "targeting ligand" is meant a molecule that has binding affinity for a moleculQ on tbe surface of a desired targeted cell. A "hybrid envelope protein", as 30 used herein, is a protein that includes a portion of a viral envelope protein ~or a biologically active analog thereof) covalently linked to a targeting ligand. For example, by a "hybrid immunoglobulin-env protein" is meant a portion of an immunoglobulin covalently linked to 35 a portion of an envelope protein. A "hybrid envelope W O 93/20221 ~ 1 3 3 4 1 1 " , `, PC~r/US93/02957 gene" i~ a nucleic acid that provides genetic instructions for a hybrid envelope protein. By "hybrid anti-carcinoembryonic antigen-specific immunoglobulin" is meant a hybrid immunoglobulin-env protein that 5 specifically binds to a carcinoembryonic antigen.
The term "fragment", as applied to an envelope protein fragment, includes some but not all of the envelope protein. A fragment will ordinarily be at least about about 20 amino acids, typically at least about 30 10 amino acids, usually at least about 40 contiguous amino acids, preferably at least about 50 amino acids, and most preferably at least about 60 to 80 or more contiguous amino acids in length. Fragments of an envelope protein can be generated by methods known to those skilled in the 15 art (e.g., those described herein~.
A biologically active fragment of a viral anvelope protein is one that possesses at least one of the following activities: a) it can bind to a cell membrane if given the appropriate targeting ligand; b) it can 20 enable fusion with a cell membrane; or c) it can enable incorporation of proteins into a mature viral-particle.
These three biological activities can be performed by the same envelope protein fragment, or by two separate envelope protein fragments. As stated above, the 25 envelope fragments of this invention do not facilitate recognition or binding of the virus' normal host cell.
This is accomplished by either destroying the activity of the normal receptor binding region by mutation, or by physically deleting it. A new recombinant receptor-30 binding region i8 added in its place. The ability of acandidate fragment to exhibit a biological activity of a viral envelope protein can be assessed by methods known to those skilled in the art.
The envelope fragment may include the amino acid 35 sequence of a naturally-ocurring viral envelope or may be WO93/20221 '~1 3 3 4 1 I PCT/US93/02957 a biologically-active analog thereo~. The biologLca activity of an envelope analog is assessed using the methods described herein for testing envelope fragments for activity.
S Applicants have provided an efficient and reliable means for ~pecifically delivering therapeutic genes or antisense nucleic acids to particular animal, plant or .
human cell types, or to cells of infectious agents.
Their method facilitates treatments for mutagenically 10 acquired, infectious, or inherited diseases, e.g., by either 1~ antagonizing the effect of an existing cellular ~; gene; 2) complementing the defect of an existing cellular gene; 3) destroying the target cells through the introduction of new genetic material; or 4) changing the 15 phenotype of the target cells through the introduction of ` new g-netic material. To specifically target cells for delivery, a hybrid envelope protein (e.g., an envelope-antibody or envelope-ligand hybrid) is utilized which directs specific interaction with a particular target 20 host cell. The viru~es itself, through its efficient internalization mechanisms, facilitates efficient uptake of the therapeutic gene. Such viral vectors are uniquely ~; adapted to deliver genes, RNA, or drugs to cell surface proteins that do not normally internalize.
Another advantage of this invention is that it overcomes the problem of gene regulation encountered with other methods of gene therapy. ~enetically-altered cells must not only synthesize the gene products at the right location, at the right time, and in the right amounts, 30 but must also be regul~ted in the ~me manner as the indigenous tis~ue. That is, the transduced cells must also have all the proper signal transduction mechanisms to respond to extracellular signals. This may be a problem in gene therapy for diabetes, for example, where 35 transplanting fibroblasts with insulin genes can be ' , W O 93/20221 ~ -~ 3 3 4 1 I PC~r~US93/02957 ineffective or even harmful. As fibroblasts do not contain the same receptors and signal transduction machinery as pancreatic beta cells, the insulin genes may be expressed differently. Targeting genes to the right 5 cells insures that the genes will be properly regulated.
In an additional aspect of the invention, a selection scheme is devised for creation of hybrid envelope protein-containing viruses. This strategy will be feasible for env proteins fused with immunoglobulins 10 or with any ligand that recognizes specific receptors on cells.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
I5 Detailed Description The drawings will first briefly be described.
Drawinas FIG. 1 is a representation of a scheme for constructing retroviral vector pLNCX*.
FIG. 2 is a representation of a scheme for constructing plasmid LNCenvpA.
FIG. 3 is a representation of a scheme for constructing plasmid LNC~nv.
FIG. 4 is a representation of a scheme for 25 constructing plasmid pUC Star-Sig.
FIG. 5 is a representation of a scheme for constructing plasmid LNC-Sig.
FIG. 6 is a representation of a scheme for ` constructing plasmid LNC-ant~CEA.
FIG. 7 is a representation of plasmids used in the construction of targeted viruses.
FIG. 8 is a representation of a strategy for generating targeted retroviruses involving construction of hybrid immunoglobulin-env genes in vitro.
2~33~1, , j WO93/20221 ~ ~, PCT/US93/02957 FIG. 9 is a representation of a strategy ~or generating targeted retroviruses involving generation of pooled virus constructions.
FIG. lo is a representation of a strategy for s generating targeted retroviruses involving selection and characterization of targeted virus.
FIG. 11 is a representation of a plasmid containing a targeted retroviral vector.
FIG. 12 is a representation of a scheme for 10 constructing plasmid pU~ Star-antiCEA.
FIG. 13 is a representation of an alternative scheme for constructing plasmid LNC-antiCEA.
What follows is a procedure for the delivery of genes to target cells using targeted viral vectors. To 15 create and target a virus, the receptor recognition domain of the viral envelope protein is replaced with a ligand directed against a specific cell surface receptor.
The hybsid envelope protein is incorporated into the ~ viral envelope during the budding proce~s, producing a - ~ 20 hybrid virus ~n v~vo. Upon infection of a host, the ~ . ~
hybrid virus specifically recognizes its target cell and resultant fusion with that cell facilitates internalization (into the target cell) of viral genes, including the therapeutic gene(s) which are engineered 25 into the viral genome. Such internalization can be extremely important; for example, immunotoxins, although efficient at delivering toxin molecules to target cells, are often clinically ineffective since the cell surface molecules to which they are targQted do not ~nternalize, 30 and internalization is re~uired for entry of the toxin molecules into the cells ~Waldmann, T.A., 1991, Sc~ence 252: 1657-1662). Targeted viruses circumvent this requirement for receptor internalization since the virus itself contains the necessary cell fusion machinery (Gilbert, J.M., et al., 1990, J Virol 64: 5106-5113;
~, WO93/20221 ~ 3 3 9 1 1 PCT/US93/02957 Roizman, B. et al., 1990, in BN Fields, et al., eds.
Viroloov, Raven Press, Ltd. New York).
General Reauirements for Taraeted Viruses In general targeted viruses are constructed by 5 replacing the receptor recognition domain of the viral envelope protein with a ligand directed against a specific cell surface receptor. The ligand can be, without limitation, an immunoglobulin (e.g., FAb, dAb, Fd, or Fc), a hormone, or any other synthetic or natural 10 protein that can direct the binding of the targeted viruses to a cell surface molecule. The ligand is biologically incorporated into the viral envelope by genetic fusion with that portion of the normal viral envelope protein involved in viral assembly and budding.
15 The envelope portion of the hybrid protein consists of an envelope fragment (or analog thereof) that is sufficient to direct efficient incorporation of the envelope hybrid :`
protein into the viral envelope. Preferably, the ;~ envelope hybrid protein no longer directs an interaction 20 between the virus and ~ts normal host cell.
It has been demonstrated that changing~the receptor specificity of the envelope protein of a virus changes the virus's tropism. `For example, vesicular stomatitis virus (VSV) pseudotypes that have their virus 25 envelope replaced with that of a retrovirus acquire the ability to infect retrovirus infectable cells (Schnitzer, T.J., et al., 1977, J Gen Virol 23:449-454; Zavada. J., et al., 1~72, J Gen Virol ~:183-191), indicating that species specific protein-protein interactions between a 30 virus core protein and an envelope protein are not critical for v~rus fusion and penetration at least in these cases~ Moreover, previous experiments have also indicated that virus envelopes can tolerate changes in ~ length or conformation introduced into the envelope -~ 35 protein, e.g., by a conjugated ligand. For example, ' ;:
WO93t20221 ~ ~ 334t~ ` PCT/US93/02957 Gitman et al. have shown that Sendai virus envelo~es reconstituted with viral envelope glycoproteins, chemically cross-linked to anti-erythrocyte antibodies acquire the ability to bind to erythrocytes that had been 5 stripped of the normal virus receptor. Similarly, Sendai ; virus envelopes reconstituted with envelope proteins, chemically cross-linked to insulin molecules, were able to bind to receptor-stripped erythrocytes expressing the insulin receptor. In both cases, envelope binding but lO not fusion occurred with the receptor-stripped erythrocytes. Fusion between the conjugated envelopes and erythrocytes occurred, however, when the conjugated~
e m elopes were coreconstituted with t~e normal viral hemagglutinin/neuraminidase and fusion proteins (Gitman, 15 A.G., et al., 1985, Biochem 24:2762-2768).
, ` Preferably, the targeted virus contains l) a viral envelope derived from a host cellular membrane; 2) a transmembrane hybrid envelope protein that directs the binding and penetration of the virus to specific target 20 cells; 3) a transmembrane envelope protein that directs he fusion of the targeted virus with the cel~ular membrane of the targeted cell for viral penetration (e.g., the targeting protein itself or another envelope protein); 4) viral core proteins; 5) a foreign gene(s) of 25 interest; and 6) all necessary viral and genetic components for penetration and expression of genes contained in the viral genome. The transmembrane hybrid envelope protein consists of l) determinants that enable the hybrid protein to become processed and incorporated 30 into viral envelopes; 2) det~rminants that enable fus~on of the viral envelope with the targeted cellular membrane; these are essential for penetration of the targeted virus; 3) a ligand determinant that enables the targeted virus to recognize and bind to specific 35 receptors on target cells. The viral genome may also ~:~
W093/20221 ~ 1 3 3 4 1 1 PCT/US93/02957 include bacterial selectable markers (e.g., ampicillin resistance) andlor a mammalian cell selectable marker (e.g., neomycin resistance).
The transmembrane hybrid protein is constructed S genetically by ~plicing the cell surface receptor binding domain of a ligand gene to a portion of the viral envelope protein gene. The transmembrane hybrid protein must retain those portions of the envelope protein that direct the effioient post-translational processing, lO sorting and incorporation of the protein into the viral envelope.
The following domains must be considered in constructing the hybrid ligand-envelope protein:
l. The receptor bindina domain ;~ 15 The receptor binding domain is that portion of the envelope protein that recognizes and binds to cell ~urface receptors. In hybrid envelope proteins, this ; portion of the envelope protein is replaced with ligand sequences. The receptor binding domain of retrovirus 20 envelope proteins h~s bQen localized to the SU subunit (Coffin, J.M., l990, in BN Fields, et al., ed~. Virology, Raven Press, Ltd., New York). Since the SU protein of retroviruses is coded for 5' to the transmembrane pro~ein, replacement of the amino-terminal sequences of 25 the envelope protein with ligand sequences poses no pro~lem for the creation of a functional hybrid ligand-envelope protein.
2. Proteolytic cleavaae site The envelope protein of retroviruses is 30 synthesized as a polyprotein which is later proteolytically cleaved to form SU and TM heterodimers.
In construction of the hybrid ligand-envelope protein, the proteolytic cleavage site should b~ eliminated. Tbe proteolytic cleavage site sbould be eliminated either by 3S deletion or by site directed mutagenesis. Perez and W093/20221 ~3341~` ~ i PCT/US93/02957 Hunter have demonstrated that elimination of the proteolvtic cleavage site does not block transport or surface expression of Rous sarcoma virus envelope proteins (Perez, L.G., et al., 1987, J Virol ~1:1609-5 1614).
3. Oligomerization domain The envelope proteins of many animal viruses associate to form trimers (Fields, B.N., et al., 1991, Virology, 2nd ed., Raven Press, Ltd., New York).
10 Trimerization of the envelope protein is thought to be essential for the proper transport and insertion of envelope proteins into the viral envelope (Singh, J. et al., l990, Embo J 9:631-639; Kreis, T.E., et al., 1986, Cell 46:929-937). Therefore it is important that this 15 domain be retained in the hybrid ligand-envelope protein.
The~tri~erization domain likely resides in the transmembrane TN protein of retroviruses (Einfeld, D., et al., 1988, Proc Natl Ac~d Sci USA 85:8688-8692); hence, creation of a functional hybrid ligand-envelope; 2Q rètroviral protein lacking the æu subunit is possible.
Some viral envelope proteins may oligomerize to form stoichiometric combinations other than trimers.
10 Trimerization of the envelope protein is thought to be essential for the proper transport and insertion of envelope proteins into the viral envelope (Singh, J. et al., l990, Embo J 9:631-639; Kreis, T.E., et al., 1986, Cell 46:929-937). Therefore it is important that this 15 domain be retained in the hybrid ligand-envelope protein.
The~tri~erization domain likely resides in the transmembrane TN protein of retroviruses (Einfeld, D., et al., 1988, Proc Natl Ac~d Sci USA 85:8688-8692); hence, creation of a functional hybrid ligand-envelope; 2Q rètroviral protein lacking the æu subunit is possible.
Some viral envelope proteins may oligomerize to form stoichiometric combinations other than trimers.
4. Fusion domain The fusion domain is a hydrophobic stretch of 25 amino acids that is involved in fusion of the virus envelope with the cell membrane ~Wiley, D.C., et al., 1990, in Fields, B.N. et al., eds. Yiroloqy, 2nd ed., Raven Press, Ltd., New York). Viral fusion allows entry of the viral core proteins and genome into the cell. In 30 influenza virus, the fusion domain, located in the amino terminus of the envelope HA2 protein, is sequestered in the hemagglutinin trimer until a low pH-induced conformational change allows presentation of the fusion domain to the cell membrane. Trimerization of the ; 35 envelope proteins can prevent constitutive expression of , ~
:^``
wo g3/2022- ~ 1 3 3 4 1 1 rcT/us93/029s7 fusion activity by sequestering it within an internal hydrophobic pocket. A potential fusion domain has been located within the extracellular portion of the gp37 TM
protein of Rous sarcoma virus (Hunter E. et al., 1983, J
S Virol 46: 920-936). Similar hydrophobic fusion sequences have been noted in the plSE protein of Moloney murine leukemia virus (Mo-MuLV) (Chambers, P., et al.,l990, J
Gen Virol ~1: 3075-3080).
In constructing a hybrid ligand-envelope protein, 10 it may be necessary to eliminate the fusion domain to pr vent the possibility of constitutive fusion activity, ~; a state that may impair the infectivity of targeted viru-es~. Therefore two proteins may be incorporated into the viral envelope of targeting viruses. The first -15 protein i8 the hybrid ligand-envelope protein which directs targeting of the virus but lacks fusion activity.
The~s-cond protein is an envelope protein possessing fusion activity but lacking a receptor binding domain.
This type of situation is observed for paramyxoviruses 20 where one envelope protein is dedicated to targeting while ~nother carries out fusion (Xingsbury, D.W., 1990, B.N~ Fields, et al., eds. Yirology, 2nd ed., Raven Press, Ltd., New York.). Where it is not necessary to prevent constitutive fusion activity, both activities may 25 be included in one protein.
:^``
wo g3/2022- ~ 1 3 3 4 1 1 rcT/us93/029s7 fusion activity by sequestering it within an internal hydrophobic pocket. A potential fusion domain has been located within the extracellular portion of the gp37 TM
protein of Rous sarcoma virus (Hunter E. et al., 1983, J
S Virol 46: 920-936). Similar hydrophobic fusion sequences have been noted in the plSE protein of Moloney murine leukemia virus (Mo-MuLV) (Chambers, P., et al.,l990, J
Gen Virol ~1: 3075-3080).
In constructing a hybrid ligand-envelope protein, 10 it may be necessary to eliminate the fusion domain to pr vent the possibility of constitutive fusion activity, ~; a state that may impair the infectivity of targeted viru-es~. Therefore two proteins may be incorporated into the viral envelope of targeting viruses. The first -15 protein i8 the hybrid ligand-envelope protein which directs targeting of the virus but lacks fusion activity.
The~s-cond protein is an envelope protein possessing fusion activity but lacking a receptor binding domain.
This type of situation is observed for paramyxoviruses 20 where one envelope protein is dedicated to targeting while ~nother carries out fusion (Xingsbury, D.W., 1990, B.N~ Fields, et al., eds. Yirology, 2nd ed., Raven Press, Ltd., New York.). Where it is not necessary to prevent constitutive fusion activity, both activities may 25 be included in one protein.
5. Transmembran~_domain The transmembrane domain is a stretch of approximately twenty or more amino acids that anchor the envelope protein to the viral envelope. It is located 30 within the pl5E protein of Moloney murine leukemia virus (Chambers, et al., supra). Retention of the transmembrane domain is thought tQ be essential since deletion of the transmembrane domain results in secretion of the synthesized envelope protein (Peres, L.G., et al., 35 1987, J Virol ~:2981-2988).
W093/20221 ~3~ 4~ PCT/US93/02957
W093/20221 ~3~ 4~ PCT/US93/02957
6. Virus buddina domain Amino acid sequences within the envelope protein may be involved with the exclusive incorporation of viral envelope proteins into viral envelopes and with virus 5 budding~ The virus budding domain directs the hybrid ligand-envelope protein into the viral envelope. These ~equences are thought to reside within the portion of the envelope protein facing the inside of the virus and may involve specific protein-protein interactions between 10 envelope proteins and viral core or matrix proteins.
Although Perez Qt al. demonstrated that deletion of the carboxy-terminal sequences of the Rous sarcoma virus env ~n protein resulted in normal budding of the mutant virus (Perez, L.G., et al., 1987, J Virol 61:2981-2988), 15 evidence exi~ts that, for other viruses, interactions between envelope proteins and viral core proteins may -~ direct virus assembly and envelopment (BN Fields, et al., eds., 1990, Viro~Vgy, Raven Press, Ltd., New York).
Although Perez Qt al. demonstrated that deletion of the carboxy-terminal sequences of the Rous sarcoma virus env ~n protein resulted in normal budding of the mutant virus (Perez, L.G., et al., 1987, J Virol 61:2981-2988), 15 evidence exi~ts that, for other viruses, interactions between envelope proteins and viral core proteins may -~ direct virus assembly and envelopment (BN Fields, et al., eds., 1990, Viro~Vgy, Raven Press, Ltd., New York).
7. Sortina 8ianal8 and other si~nals Sorting signals are determinants that direct the envelope protein to the correct intracellular location during post-translational processing. These sequences insure that the envelope protein passes through the endoplasmic reticulum, Golgi apparatus, and other 25 organelles until it eventually reaches the viral envelope. Other signals that may have to be retained in the hybrid ligand-envelope protein are glycosylation sequences and sequences involved in effective conformation of the envelope protein (e.g., disulfide 30 bonds).
8. Sional seauence The signal sequence is an amino-terminal hydrophobic stretch of amino acids that directs the envelope protein into the endoplasmic reticulum. The 35 signal sequence, which is later proteolytically cleaved, W093/20221 ~1 3 3 411 PCT/US93/02957 is essential for the hybrid ligand-envelope protein to become located in a membrane.
The diversity of signals and domains that must be considered in constructing targeted viruses requires that S precise and correct splicing of ligand and envelope genes occur. The present invention-describes a selection scheme for constructing targeted viruses whereby the ligand gene is spliced to an envelope gene fragment; this hybrid gene codes for those portions of the envelope 10 protein which are required to direct efficient incorporation of the resultant hybrid envelope-ligand protein into the mature viral particle. According to the selection scheme, cell surface receptor binding domains of ligand genes are randomly ligated to progressive 15 deletions of viral envelope genes. The correct co bination of ligand and envelope sequences is determined by a selection scheme for the production of bioiogically active targeted virus. The selection scheme -not only produces targeted virus but simplifies the 20 construction of future targeted viruses.
~; a,~peoific Exam~l~ of a Taraeted ~etrovirus There now follows an example of a recombinant retrovirus which targets and infects particular host cells for the purpose of delivering to those cells a 25 desired therapeutic gene. This example is provided for the purpose of illustrating, not limiting, the invention.
Moloney murine leukemia virus (Mo-MuLV) is a mouse ecotropic retrovirus. A recombinant Mo-NuLV based retroviral vector that is targeted to colon cancer cells 30 is constructed. The targeted retroviral vector delivers the neomycin resistance gene to colon cancer cells.
Targeting to human colon cancer cells is accompl~shed by incorporating into the viral envelope hybrid i D unoglobulin-env proteins directed against 35 carcinoembryonic antigen. Carcinoembryonic antigen (CEA) WO93/20221 2 13 3 4 ~ ~ PCT/USg3/02957 is a tumor associated antigen expressed on the surface of human colon cancer cells but not on the surface of normal adult cells. The CEA glycoprotein, possessing multiple membrane spanning alpha helices, does not internalize in 5 response to ligand (Benchimol, S. et al., 1989, Cell 57:327-334). A protein that is homologous to - carcinoembryonic antigen has recently been shown to be the receptor for mouse hepatitis virus (Dveksler, G.S., et al, 1991, J Virol 65:6881-6891).
For the purpose of this illustration, a single ~ variable region of the heavy chain of anti-CEA is fused ; to a portion of the env gene. Single variable heavy `~ chain fragments (dAb) have been shown to be as effective in antigen binding as fragmented antibodies (FAb), 15 oontaining both beavy and light chain fragments, and intact monoclonal antibodies (Ward, E.S., et al., Nature 544-546). The function of immunoglobulin-env proteins is not limited, however, to the use of dAb's and ~- can be applied with FAb's, Fv's and mAb's.
20 Modification of the retroviral vector LNCX
: ~ ~ LNCX i8 a Moloney murine leukemia virus based etroviral vector contained in the plasmid pLNCX (Miller, A.D., et al., 198~, Biotechniques 7:980-990). pLNCX
contains a unique HindIII and ClaI cloning site for 25 expression of inserted genes, a cytomegalovirus ~CMV) promoter, a polyadenylation site (pA), retroviral long terminal repeats (LTR) for retroviral RNA transcription and reverse transcription, a bacterial neomycin resistance gene (Neo) which conveys resistance to both 30 neomycin and G418, a bacterial origin of replication (Or), a bacterial ampicillin resistance gene (Amp), and a retroviral RNA packaging seguence (~). LNCX is modified to contain a unigue SalI site as shown in Figure 1.
pLNCX is Iinearized with XbaI and subcloned into the XbaI
35 site of the phagemid BluescriptII SX~ (Stratagene, La ~ " ~
WO93/20221 ~ l 3 3 4 1 1 PCT/US93/02gS7 Jolla, CA). Single stranded DNA is purified and the unique BstEII site of LNCX is converted into a SalI site by site directed mutagenesis with the oligonucleotide 5'-GCAGAAGGTCGACCCAACG-3 ' (SEQ ID NO: 1) . The BstEII
5 site is located within the extended packaging signal (~+) of Mo-NuLV RNA (Bender, M.A., et al., 1987, J V~rol Çl:1639-1646; Adam, M.A., et al., 1988, J Virol 62:3802-3806; Armentano, D. et al., 1987, J Virol 61:1647-1650).
Conversion of the BstEII site to SalI does not affect 10 packaging since this region has been determined to be dispens~ble for efficient packaging (Schwartzberg, P., et al., 1983, J V~rol 46:538-546; Mann R. et al., 1985, J
Virol 54:401-407; and Mann, R., et al., 1983, Cell 33:153-159). The BstEII site is converted into a SalI
15 site because BstEII sites, but not SalI sites, frequently occur in heavy chain genes (Chaudhary, V.K., et al, 1990, Proc Natl Acad Sci USA 87:1066-1070). The SalI
containing plasmid is recircularized with XbaI and DNA
ligase to form the plasmid pLNCX*.
20 Clonina of the Mo-Mu~V env ~rotein in p~NCX*
The Mo-NuLV env gene is cloned into pLNCX* as shown in Figure 2. The Mo-MuLV env gene is excised from plasmid p8.2 (Shoemaker, C., et al., 1980, Proc Natl Acad ' Sci USA 77: 3932-3936) as a 1.9kb ScaI-NheI fragment. The 25 l.9kb ScaI-NheI fragment contains the entire coding region for the pl5E transmembrane protein and the majority of tha coding region for the gp70 SU protein.
The 5'-protruding ends are digested with Sl-nuclease, and HindIII linkers (5-CCAAGCTTGG-3'; SEQ ID N0: 2) are 30 added. The env gene is cloned as a HindIII fragment in the HindIII site of pLNCX* to form plasmid LNCenvpA. The orient~tion of the HindIII env fragment is such th~t it can be transcribed and expressed from the cytomegalovirus ~; (CNV) promoter.
:; :
WO93/20221 ~33 ~ PCT/US93/02957 Modification of LNCenvpA to LNCenv LNCenvpA is cloned as an XbaI fraament in phagemid pBluescript II SK~ for additional site directed mutagenesis (Figure 3). The env encoding HindIII
5 fragment contains a polyadenylation signal that may interfere with the polyadenylation signal provided by the viral vector. The AAUAAA polyadenylation signal is therefore changed to AAGAAA by site directed mutagenesis with the oligonucleotide 5'-GTTTTCTTTTATC-3' (SEQ ID NO:
10 3). The HindIII site located at the 3' end of the env gene is eliminated by site directed mutagenesis with the oliqonucleotide 5-CAAGCATGGCTTGCC-3' (SEQ ID NO: 4). The env containing retroviral vector is recircularized by XbaI restriction and ligation to form plasmid LNCenv.
15 Molecular clonina of anti-CEA immunoalobulin aenes cDNA encoding the mature variable region domain of ~ ~ anti-CEA heavy chain genes is cloned as an XhoI-SpeI
;~ fragment using the polymerase chain reaction (PCR) and RNA template. RNA is derived from the spleen of mice 20 immunized against purified carcinoembryonic antigen.
~::
Alternat~vely, RNA can be derived from hybridoma cell lines that ~ecrete monoclonal antibodies against CEA, e.g., 1116NS-3d (American Type Culture Collection CRL80~9) or CEA 66-E3 (Wagener, C., et al., 1983, J
2S Immunol 130:2308-2315).
The following PCR primers hybridize to cDNA
encoding the aminoterminal end of mature heavy chain genes (Stratacyte, Inc.). The degenerate primers introduce an XhoI site which is underlined.
W~93/20221 ~ ~ 3 ~ PCT/US93/02~7 5' AGGTGCAGCTGCTCGAGTCGGG 3' (SEQ ID NO: 5) 5' AGGTGCAACTGCTCGAGTCGGG 3' (SEQ ID NO: 6) S~ AGGTGCAGCTGCTCGAGTCTGG 3' (SEQ ID NO: 7) 5' AGGTGCAACTGCTCGAGTCTGG 3' (SEQ ID NO: 8~
5' AGGTCCAGCTGCTCGAGTCTGG 3' ~SEQ ID NO: 9) XhoI
The f~llowing PCR primer hybridizes to immunoglobulin heavy chain mRNA within the region coding for the J-region and introduces SpeI and BstEII sites.
5' CTATTAACTAGTGAC~GTTACCGTGGTCCCTTGGCCCCA 3' (SEQ
ID NO: 10) SpeI BstEII
The amplified anti CEA variable hea~y chain DNA is cloned as an XhoI-SpeI fragment in an ImmunoZ~P H vector (Stratacyte, Inc.) (Mullinax, R.I. et al., 1990, Proc Natl Acad Sci USA 87: 8095-8099). ImmunoZAP H is a modified lambdaZAP vector that has been modified to express in E.coli immunoglobulin variable heavy chain fragments behind a pelB signal sequence. The procadure 20 could similarly be performed by expressing immunoglobulin variable light chain fragments in a packaging cell line.
Identi~ication of hiah affinitY anti-CEA clones Clones expressing high affinity anti-CEA
antibodies axe identified by a f ilter binding assay . The 25 anti-CEA phage library i6 screened by nitrocellulose plaque lifts with ~l25I]bovine serum albumin conjugated to CEA, as previously described (Huse, W.l)., et al., 1989, Science 246:12~5-1281). High and intermediate affinity anti-CEA clones are chosen for further manipulation.
30 Construction of plasmid LNC-immuno~lobulin Two strategies are presented for creating plasmid LNC-immunoglobUlin ( in this example, LNC-an~iCEA, which codes for an anti-CEA immunoglobulin gene). LNC-immunogl o~ul in vectors encode an immunoglobulin peptide W O 93/20221 ~1 ~3~ P~r/US93/02957 fused to an amino-terminal signal se~uence. Some amino acidæ at the amino-terminal end of the mature immunoglobulin peptide have been modified by the PCR
primers used to generate the immunoZAP library.
5 Moreover, the design of the LNC-antiCEA plasmid results in the insertion of an extra amino acid at the amino terminal end. These amino acid changes do not affect antigen binding because 1) ~he amino acid changes are conservative; 2) the affected amino acids are normally 10 variable at those sites; and 3) the affected amino acids occur within the framework region of immunoglobulins`
which has been shown not to participate in antigen binding or conformation of the antibody (Relchman et al.
1988 Nature 332:323-327). It is for these same reasons 15 that cleavage o* the signal seguence from mature peptide will not be affected.
~ Both strategies for creating LNC-immunoglobulin ; ~ rely on the use of plasmid pUC Star-Sig, the construction of which is presented below.
An immunoglobulin signal sequence is cloned into a modified pUCll9 vector to create pUC Star-s~g.as follows (Figure 4). pUCll9 is a phagemid containing a polylinker cloning site. The multiple cloning sites of pUCll9 are replaced with new restriction sites by insertion of the 25 following polylinker into the HindIII and XbaI sites of pUCll9.
Hind~I P~tI XhoI BclI SpeI NotI ClaI Xbal 5'-AGCTTCTGCAGGCTCGAGTGATCAACTAGTGCGGCCGCATCGATT-3' (SEQ
ID N0: 11) 30 3'-AGACGTCCGAGCTCACTAGTTGATCACGCCGGCGTAGCTAAGATC-5'(SEQ
ID N0:12) The modified pUCll9 is called pUC Star-l (Figure 4). The restriction sites may be further separated by small W093/20221 ~ 1 3 3 g 11 rCT/US93/02957 linkers, if adjacent restriction siteæ interfere with one another during digestion.
The signal sequence from an anti-NP immunoglobulin heavy chain gene is isolated from plasmid pcDFL.l (Ucker, S D.S., et al., 1985, J Immnol 135:4204-4214) as a -330bp PstI fragment. The 330bp PstI fragment is subcloned into pUC Star-l to yield plasmid pUC Star-Sig (Figure 4). The PstI fragment is oriented so that the signal sequence can be expressed.
o a. Cons~uç ~ on of L;NC-immunoalobulin through plasmid LNC-Sig. an immunoalobulin expression vector.
LNCX* is converted into a eukaryotic immunoglobu}in expression vector (Figures 4 and 5). An immunoglobulin heavy chain signal sequence and XhoI-SpeI
15 cloning sites are inserted behind the CMV promoter of plasmid LNCX* to allow expression of the PCR amplified im~unoglobulin genes. Conversion of LNCX* is as follows.
The immunoglobulin heavy chain signal sequence is recovered from pUC Star-Sig a8 a HindIII-ClaI restriction 20 fragment ~nd cloned into the HindIII-ClaI sites of LNCX*.
The resulting plasmid, LNC-Sig contains a retroviral vector with the immunoglobulin heavy chain signal sequence under control of the CMV promoter (Figure 5).
An anti-CEA gene from the immunoZAP library is 25 then subcloned into LNC-Sig to form plasmid LNCanti-CEA.
This generates an anti-CEA variable heavy chain gene containing a signal sequence (Figure 6). The anti-CEA
gene is first excised from immunoZAP phage DN~ as a Bluescript SK- phagemid (see lambdaZAP protocols, 30 Stratagene, Inc. La Jolla, CA). The anti-CEA gene is purified as an XhoI-SpeI fragment and l~gated to XhoI-SpeI restricted LNC-S~g. LNC-Stg contains three SpeI
sites. Therefore, to generate plasmid LNCanti-CEA, the ligation mix is transformed into neomycin-sensitive, 35 ampicillin-sensitive E. coli and neomycin-resistant, WO93/20221 ~ 3 3 4 l i PCT/US93/02957 ampieillin-resistant transformants are selected for.
Plasmid LNCanti-CEA is sereened from neomycin-resistant, ampieillin-resistant trans~ormants by using the SpeI-XhoI
anti-CEA restrietion fragment from Bluescript SK-anti-CEA
5 as a probe. The SpeI site is used because of dependenee upon the available sites in the ImmunoZap expression veetor. To simplify eonstruetion of LNCanti-CEA, a unique NotI site ean be introdueed into the ImmunoZap H
expression veetor so that NotI sites ean be used instead lO of SpeI sites.
. Construetion of LNC-immunoalobulin throuah Plasmid pUC Star-Sig An anti-CEA gene from the immunoZAP library is subeloned into plasmid pUC Star-Si~ to form plasmid pUC
15 Star-anti-CEA. This generates an anti-CEA variable heavy ehain gene eontaining a signal sequenee (Figure 12). The anti-CEA gene is exeised from immunoZAP phage DNA as a Blueseript SK-phagemid (~ee lambdaZAP protoeols, Stratagene, Ine., La Jolla, CA). Blueseript SX-anti-CEA
; 20 double ~tranded DNA ~8 prQpared and restrieted with XhoI
and SpeI. The anti-CEA eontaining XhoI-SpeI f~agment is purified by eleetroelution and ligated to Xho-SpeI
restrieted pUC Star-Sig to ereate plasmid pUC Star-antiCEA ~Figure 12).
The antiCEA gene is transferred from pUC Star-anti CEA to LNCX* as a HindIII-ClaI fragment to ereate plasmid LNC-antiCEA (figure 13). The antiCEA-eontaining HindIII-ClaI fragment is purified from pUC Star-antiCEA by eleetroelution. Phosphatase treated, HindIII-ClaI
30 restrieted LNCX* is ligated with the purified HindIII-ClaI antiCEA fragment to generate LNC-antiCEA ~figure 13).
Strateov for generatina targeted viruses The starting materials for generation of targeted 35 viruses are the LNC~nv and LNC-immunoglobulin lin this ~ .
.~'`~, .
W O 93/20221 . X 1 ~ 3 4 1 1 P{~r/US93/02957 example, LNC-antiCEA) plasmids shown in Figure 7.
Figures 8-11 diagram the general principle for the primary generation of targeted viruses. Hybrid i Dunoglobulin-env proteins are generated that target 5 viruses to cells expressing carcinoembryonic antigen.
Since the location of important determinants for envelope protein sorting (S), trimeriza~ion (T), and fusion (F) iæ
; not known with certainty, the i D unoglobulin gene is ligated to progreæsive deletions of the env gene and 10 functional i D unoglobulin-env hybrids are selected for.
Useful Envelo~e Fraoments or Analogs The envelope portion of the fusion protein may consist of any portion of the envelope protein (or any analog thereof) which is sufficient to direct efficient 15 incorporation of the envelope fusion protein into the viral coat ~upon budding of the recombinant virus from a producer cell line). Suc~ fragments or analogs may be determined using the following general selection scheme which generally involves ligation of cell surface 2Q receptor binding domains of ligand genes to progessive deletions of viral envelope genes. The correct combination of ligand and envelope sequences is determined by a selection scheme for the production of biologically active targeted virus. The selection scheme 25 not only produces targeted virus but simplifies the construction of future targeted viruses.
Construction of hvbrid immunoalobulin-env genes in v~txo Plasmid LNCenv contains the coding region for the Mo-MuLV env polyprotein (Figure 8). LNCenv is first 30 linearized by HindIII restriction. A rangQ of deletions extending into the env gene is created by colleoting aliquots of Exonuclease III treatqd DNA over time and removing 5'-processive ends with Sl-nuclease (Guo, I.H., et al., 1983, Methods Enzymol 100:60; and Sambrook, J., 3S et al., 1989, Molecular Clonina, Cold Spring Harbor ` ~
Laboratory Press, Cold Spring Harbor). NotI linkers (5' AGCGGCCGCT 3 ' SEQ ID N0: 13) are ligated onto the blunt end termini and restricted with NotI. This results in a NotI restriction overhang at the 5'-border of every 5 deletion within the env gene. The NotI overhangs at the other end of the molecules are removed by SalI
restriction of the reaction mixture. The reaction mixture is then treated with phosphatase to prevent circularization of the re~ction products.
The reaction mixture is ligated to a SalI-NotI
restriction fragment from LNC-antiCEA that contains the ~` anti-CEA variable heavy chain gene. This creates a pool of functional retroviral vectors encoding an anti-CEA
peptide fused to a series of env deletions.
15 Generation of Dooled virus constructions The total reaction mixture from above is transformed into ampicillin-sensitive E. coli and ampicillin resistance is selected for tFigure 9).
Reoombinants containing functional retroviral vectors are 20 selected for since only they contain the ampicillin resistance gene. Plasmid DNA is prepared from~
transformants grown in liquid culture to create a pool of retroviral vectors containing different immunoglobulin-env fusion genes.
The DNA is tranæfected into the crip2 retroviral packaging cell line (Danos, 0., et al., 1988 , Proc Natl Acad Sci USA 85: 6460-6464). Alternatively, DNA is transfected into a packaging cell line that does not encode wild-type env protein. The transfected packaging 30 cell line synthesizes each of the different hybrid immunoglobulin-env protein~ as well as the wild type env protein (encoded by an env gene contained in the cell line). The transfected packaging cell line secretes a pool of enveloped retroviruses containing the different 35 `retroviral genomes encoding hybrid immunoglobulin-env `` WO93/20221 ~ 1 3 3 ~ PCT/USg3/02957 genes. If the hybrid immunoglobulin-env protein retained all of the neeessary determinants for efficient incorporation into viral envelopes then the hy~rid-env protein ean be incorporated into viral envelopes. Wild 5 type env proteins eneoded for by the packaging eell line are also ineorporated into the viral envelopes. This ereates a virus eontaining both wild type and hybrid env proteins in the viral envelope. This system therefore seleets for immunoglobulin-env hybrids that ean 10 ineorporate their gene produets into the viral envelope.
Virus pools are harvested from media filtered at 0.45~ to remove contaminating G418-resistant paekaging eells.
Seleetion and eharaeterization of targeted virus G418-sensitive target eells are exposed to virus pools by standard proeedures, and G418-resistant eells are seleeted for. The target eells ean be any non-mouse eell line (uninfeetable by wild type No-MuLV) that expresses eareinoembryonie antigen. Examples inelude 20 ATCC COLO 205, a human eell line isolated from the aseites of a patient with eareinoma of the eo~on (A.T.C.C.#CCL 222); LR-73 CEA, a ehinese hamster ovary eell line transfeeted with a mouse eareinoembryonie antigen gene (Benehimol, S. et al., supr~); and HCT48, a 25 human eolon adenoeareinoma eell line (Shi, 2.R., et al., 1883, Can~er Res 43:4045-4049).
G418-resistant eells ean only have arisen from transduetion of the neomyein resistanee gene by targeted virus. This system therefore seleets for reeombinant 30 viruses that have hybrid immunoglobulin-~nv proteins that have retained all the neeessary determinants for viral targeting and fusion.
Reseue of inteorated i~munoalobulin-~nv gene Infeetion by targeted virus results in integration 35 of the hybrid envelope gene that ereated the targeting :
WO93/20221 PCT/US93/02~7 ~1 3 ~ 411 _ 30 ~
protein. The integrated hybrid immunoglobulin-env gene is rescued from the host DNA by polymerase chain reaction (PCR) with the following primers:
PCR 5' Rescue primer:
5 5'-CCAGCCTCCGCGGCCCCAAGCTTCTGCA-3' (SEQ ID NO: 14) HindIII
PCR 3' Rescue primer:
5'-GGTTC~SIaÇaAACTGCTGAGGGC-3' (SEQ ID NO: 15) XbaI
PCR amplification with these primers generates the immnoglobulin-env gene bordered by HindIII and XbaI
sites. The amplified DNA is restricted with HindIII and XbaI to create sticky ends and the DNA is ligated into HindIII-XbaI cut LNCX*. When transfected into crip2 15 packaging cells, this generates a retroviral vector targeted to cells expressing cell surface carcinoembryonic antigen (e.g., colon cancer cells).
The retroviral vector produced in the above selection scheme is targeted to both CEA-expressing human 20 cells (directed by the hybrid envelope protein) and normal mouse cells (directed by the wild type envelope protein) when produced in crip2 packaging cells. To create viruses that infect target cells only, the retroviral vector will first be tested to determine if 25 incorporation of the hybrid envelope protein alone is sufficient to direct virus fusion. This is accomplished by transfecting DNA into a modified packaging cell line that does not encode wild type env.
If fusion functions are found to have been 30 supplied from the wild type envelope protein, targeted viruse~ will be created as follows. A packaging cell line will be created that encodes an env gene containing mutations in the receptor binding domain. When W093~20221 PCT/US93/02g57 `~13~
transfected with the targeted viral vector DNA, targeted viruses expressing both hybrid ligand-env proteins and env proteins with mutated binding sites will be produced.
The viruses will exclusively infect target cells.
5 The taraeted viral vector is a universal vector The viral vector that is constructed by the above procedure is a universal targeted vector (Figure 11).
Targeting to other cells is accomplished by replacing the XhoI-SpeI anti-CEA fragment with any XhoI-SpeI fragment 10 encoding an in-frame immunoglobulin or ligand directed against specific cell surface proteins. For example, an XhoI-SpeI i D unoglobulin-containing fragment from an immunoZAP library can be fused in frame behind a signal sequence and subcloned into LNCX* through the pUC Star-15 Sig plasmid, as outlined above. Substituting a SalI-NotI
fragment from another LNC-immunoglobulin plasmid into the universal vector would create another targeted virus vector.
Other Viral Vectors Any enveloped virus may be used as a vector for the targeted delivery of a therapeutic gene. Particular examples include both DNA and RNA viruses, such as Herpesviridae, e.g., herpes simplex type 1 or 2, Paramyxoviridae, Retroviridae, Hepadnaviridae, 25 Poxviridae, Iridoviridae, Togaviridae, Flaviviridae, Coronaviridae, Rhabodoviridae, Filoviridae, Orthomyxoviridae, Bunyaviridae, or Arenaviridae, or any other, yet unclassified, enveloped virus.
An extensive selection of these viruses is 30 available, e.g., from the American Type Culture Collection.
Taraetina Liaands Any molecule that is capable of directing specific interaction with a target host cell (e.g., by specific 35 recognition of and binding to a host cell surface ~ if ~
W093/20221 2133 ~i 1 i PCT/USg3/02g57 protein) may be used as the targeting ligand portion of the envelope fusion protein. Preferably, such a protein is derived from one member of a ligand:receptor pair.
The targeting ligands are not limited to proteins.
5 Carbohydrate and lipid moieties can be attached to the envelope protein via protein fragments containing consensus ~equences for glycosylation and lipidation.
Immunoglobulin genes can be used as ligands, as shown in the example above. Genes for high affinity lO immunoglobulins are screened from a lambda or bacterial expression library by a filter binding assay with sI] bovive serum albumin conjugated to antigen, as previously described (Huse, et al. Sup~a ) .
Cell surface molecules such as integrins, adhesion l5 molecules or homing receptors can be used as cell-speaific ligands since they are involved in cell-cell interactions via receptors on other cells. Genes encoding these molecules can be identified by the panning method of Seed and Aruffo (Seed. B., et al., 1987, Proc 20 Natl Acad Sci USA 84:3365-3369).
Hormones that bind to specific receptors can be used as targeting ligands as well as viral proteins, such as ~IV envelope protein gpl20, and modifications of naturally occuring ligands.
25 Thera~eutic Genes Therapeutic genes useful in the invention include the following. l) Genes that are therapeutic to cancer cells may include a) antisense oncogenes; b) tumor suppressor genes, such as p53 or the retinoblastoma gene 30 product Rb, c) destructive toxin genes such as a diphtheria toxin gene; d) cytokines æuch as tumor necrosis factor or interferons; or e) any other therapeutic gene. 2) Therapeutic genes targeted to cells that are infected with HIV. Specific examples 35 include antisense DNA complementary to essential genes ` wo g3/2022l ~ 1 3 3 9 1 1 PCT/US93/02~7 for HIV, e.g., polymerase; destructive toxin genes, e.g., diphtheria toxin; and genes that will invoke intracellular immunity, e.g., HIV enhancer sequences that titrate and remove HIV regulatory proteins (Baltimore, 5 D., 1988, Nature 335:395-396). 3) Genes to correct inherited deficiencies. Examples include, but are not limited to, insulin genes delivered specifically to pancreatic beta cells, or the cystic fibrosis transmembrane regulator (CFTR) gene delivered to the 10 appropriate lung cells of cystic fibrosis patients. The expression of targeted genes can be further accomplished through the use of tissue specific enhancers that regulate the transgene.
Therav For any gene therapy described herein, the appropriate recombinant virus, as described above, is administered to a patient in a pharmaceutically-acceptable buffer (e.g., physiological saline). The therapeutic preparation is administered in accordance 20 with the condition to be treated. For example, to treat an HIV-infected individual, the virus is administered by direct injection, e.g., by intravenous, intramuscular, or intraperitoneal injection, at a dosage that provides suitable targeting and lysis of HIV-infected host cells.
25 Alternatively, it may be necessary to administer the targated virus surgically to the appropriate target tissue, or via a catheter, or a videoscope. It may be convenient to administer the therapeutic orally, nasally, or topically, e.g., as a liquid or spray. Again, an 30 appropriate dosage is an amount of therapeutic virus which effects a reduction in the disease.
Targeted virus can also be administered by implanting viral packaging cells into a patient. The cells can be enclosed in a semi-permeable container, 35 e.g., permeable to a virus but not permeable to a ~3~4~
WO93/20221 PCT/USg3/02957 packaging cell. The implanted container may be removable. Alternatively, the container may be hooked up to a patient intravenously, so that virus enters the patient through a needle or through a catheter. In this 5 way the patient receives a continuous dose of viral gene therapy.
Other Embodiments Other embodiments are within the following claims.
For example, replication competent viruses may be lO used in certain cases. In other cases, where replication-deficient viruses are necessary, it may be efficacious to administer modified packaging cells, rather than the targeted virus, to patients. By this method a non-proliferating dose of recombinant virus is 15 delivered to a local area, and then the virus locates the specific target cell. For example, tumor infiltrating lymphocytes (TIL), which surround cancer cells, can be modified to secrete locally high concentrations of cancer cell-targeted virus. Treatment may be repeated as 20 necessary. Immune response against targeted viruses can be overcome with immunosuppressive drugs.
In addition to colon cancer celLs, the ~irus of the invention may be used to target other cancer cells, e.g., ovarian, breast, or lung cancer cells, or cells 25 affected with hereditary diseases such a~ muscular dystrophy, Huntington's disease, or cells with a defect in adenosine deaminase. Herpesviridae viruses may include Herpes simplex type 1 or type 2, Epstein-Barr virus, or Cytomegalovirus. Sendai virus and Vaccinia 30 virus may also be adapted to this method.
~ 1 3 ~ 4 1 1 WO93/20221 . j!. PCT/US93/02~7 BBOUBNCE ~I8TING
BNERAL INFORMATION:
(i) APPLICANT: Alexander T. Young (ii) TITLB OF IN~ENTTON: GENE THERAPY USING
TARGETED VIRAL VECTORS
(~ii) NnMBBR OF 8BQ~ENCE8: 15 (iv) CORRE8POND~NCB ADDRB88:
(A) ADDRE88~B: Fish & Richardson (B) 8TR~T: 225 Franklin Street ~C) CITYs Boston (D) 8TATE: Massachusetts ~B) CO~NTRY: U.S.A.
(F) 8IP: 02110-2804 ~v) COMP~TBR R~ADABLB FORM:
(A) NEDI~ T~PB: 3.5" Diskette, 1.44 Nb (B) CO~P~TDR: IBM PS/2 Model 50Z or 55SX
(C) OPDRATING 8Y8TEM: IBM P.C. DOS (Version 5.00) (D) 8oFT~aRE: WordPerfect (Version 5.1) ~vi) C~RRENT APPLICATION DATA:
~A) APPLICATION N~NB~R:
(B) FILING DATE:
(C) C~A88IFICATION:
) PRIOR APPLIC~TION DATA:
~A) APPLI~ATIO~ N~NBER: 07/862,~95 ~B) FILING DATE: April 3, 1992 (vi~) A~TO~N~Y/AG~NT INFORMATION:
~A) NAME: Paul T. Clark (B) REGI8TRATION N~MBER: 30,162 ~C) REFERBNCE/DOC~ET NUMBER:05140/002002 ;~8) TELBCOMM~NICATION INFORMATION:
~A) TELBP~ON~: (617) 542-5070 ~B) TE$EFAS: (617) 542-8906 (C) TELE~: 200154 t WO 93/20221 ~13 ~ 4 ~ r/us93/o2957 ~2) INFORMATION FOR 8BQ~ENCB IDENTIFICATION N~NBER: 1:
(i) 8BQVBNCB C~ARACTBRI8TIC8:
~A) ~BNGT~: 19 (B) TYPB: nucleic acid ~C) 8TRANDBDNB88: single ~D) TOPO~O~Y: linear ~x~) 8BQ~NCB DB8CRIPTION: SEQ ID NO: 1:
:
~2) I~FORKATION FOR 8BQV~NCB IDBNTIFICaTION NnNBBR: 2:
) 8BQV~NCB CEaRACTERI8TIC8:
:
~A) LBNGT~: 10 (B) TYPB: nucleic acid : ~C) 8TRANDBDNB88: double tD) TOPOLOOY: linear Xi) 8BQV~NCB DB8CRIPTION: SEQ ID NO: 2:
.
2) INFORNATION FOR 8EQVBNCE IDENTIFTCATION N~MBBR: 3:
~) 8BQVBNCB C~ARACTBRI8TIC8:
~A) ~EN~T~: 13 ~B) TYPES nucleic acid ~C) 8TR~NDBDNB88: single tD) TOPOLOGYs linear ~Yi) 8BQ~ ~ CB DB8CRIPTION: SEQ ID NO: 3:
~2) INFORNATION FOR 8EQVBNCJ IDENTIFICATION N~NB~a: 4:
(i) 8BQVENCB C~ARACT~RI8TIC8s ~ ~A) ~EN~T~: 15 :~ (B) ~YP~: nucleic acid (C) 8TRAND~DNB88: single (D) TOP0~04Y: linear .
! --.~
The diversity of signals and domains that must be considered in constructing targeted viruses requires that S precise and correct splicing of ligand and envelope genes occur. The present invention-describes a selection scheme for constructing targeted viruses whereby the ligand gene is spliced to an envelope gene fragment; this hybrid gene codes for those portions of the envelope 10 protein which are required to direct efficient incorporation of the resultant hybrid envelope-ligand protein into the mature viral particle. According to the selection scheme, cell surface receptor binding domains of ligand genes are randomly ligated to progressive 15 deletions of viral envelope genes. The correct co bination of ligand and envelope sequences is determined by a selection scheme for the production of bioiogically active targeted virus. The selection scheme -not only produces targeted virus but simplifies the 20 construction of future targeted viruses.
~; a,~peoific Exam~l~ of a Taraeted ~etrovirus There now follows an example of a recombinant retrovirus which targets and infects particular host cells for the purpose of delivering to those cells a 25 desired therapeutic gene. This example is provided for the purpose of illustrating, not limiting, the invention.
Moloney murine leukemia virus (Mo-MuLV) is a mouse ecotropic retrovirus. A recombinant Mo-NuLV based retroviral vector that is targeted to colon cancer cells 30 is constructed. The targeted retroviral vector delivers the neomycin resistance gene to colon cancer cells.
Targeting to human colon cancer cells is accompl~shed by incorporating into the viral envelope hybrid i D unoglobulin-env proteins directed against 35 carcinoembryonic antigen. Carcinoembryonic antigen (CEA) WO93/20221 2 13 3 4 ~ ~ PCT/USg3/02957 is a tumor associated antigen expressed on the surface of human colon cancer cells but not on the surface of normal adult cells. The CEA glycoprotein, possessing multiple membrane spanning alpha helices, does not internalize in 5 response to ligand (Benchimol, S. et al., 1989, Cell 57:327-334). A protein that is homologous to - carcinoembryonic antigen has recently been shown to be the receptor for mouse hepatitis virus (Dveksler, G.S., et al, 1991, J Virol 65:6881-6891).
For the purpose of this illustration, a single ~ variable region of the heavy chain of anti-CEA is fused ; to a portion of the env gene. Single variable heavy `~ chain fragments (dAb) have been shown to be as effective in antigen binding as fragmented antibodies (FAb), 15 oontaining both beavy and light chain fragments, and intact monoclonal antibodies (Ward, E.S., et al., Nature 544-546). The function of immunoglobulin-env proteins is not limited, however, to the use of dAb's and ~- can be applied with FAb's, Fv's and mAb's.
20 Modification of the retroviral vector LNCX
: ~ ~ LNCX i8 a Moloney murine leukemia virus based etroviral vector contained in the plasmid pLNCX (Miller, A.D., et al., 198~, Biotechniques 7:980-990). pLNCX
contains a unique HindIII and ClaI cloning site for 25 expression of inserted genes, a cytomegalovirus ~CMV) promoter, a polyadenylation site (pA), retroviral long terminal repeats (LTR) for retroviral RNA transcription and reverse transcription, a bacterial neomycin resistance gene (Neo) which conveys resistance to both 30 neomycin and G418, a bacterial origin of replication (Or), a bacterial ampicillin resistance gene (Amp), and a retroviral RNA packaging seguence (~). LNCX is modified to contain a unigue SalI site as shown in Figure 1.
pLNCX is Iinearized with XbaI and subcloned into the XbaI
35 site of the phagemid BluescriptII SX~ (Stratagene, La ~ " ~
WO93/20221 ~ l 3 3 4 1 1 PCT/US93/02gS7 Jolla, CA). Single stranded DNA is purified and the unique BstEII site of LNCX is converted into a SalI site by site directed mutagenesis with the oligonucleotide 5'-GCAGAAGGTCGACCCAACG-3 ' (SEQ ID NO: 1) . The BstEII
5 site is located within the extended packaging signal (~+) of Mo-NuLV RNA (Bender, M.A., et al., 1987, J V~rol Çl:1639-1646; Adam, M.A., et al., 1988, J Virol 62:3802-3806; Armentano, D. et al., 1987, J Virol 61:1647-1650).
Conversion of the BstEII site to SalI does not affect 10 packaging since this region has been determined to be dispens~ble for efficient packaging (Schwartzberg, P., et al., 1983, J V~rol 46:538-546; Mann R. et al., 1985, J
Virol 54:401-407; and Mann, R., et al., 1983, Cell 33:153-159). The BstEII site is converted into a SalI
15 site because BstEII sites, but not SalI sites, frequently occur in heavy chain genes (Chaudhary, V.K., et al, 1990, Proc Natl Acad Sci USA 87:1066-1070). The SalI
containing plasmid is recircularized with XbaI and DNA
ligase to form the plasmid pLNCX*.
20 Clonina of the Mo-Mu~V env ~rotein in p~NCX*
The Mo-NuLV env gene is cloned into pLNCX* as shown in Figure 2. The Mo-MuLV env gene is excised from plasmid p8.2 (Shoemaker, C., et al., 1980, Proc Natl Acad ' Sci USA 77: 3932-3936) as a 1.9kb ScaI-NheI fragment. The 25 l.9kb ScaI-NheI fragment contains the entire coding region for the pl5E transmembrane protein and the majority of tha coding region for the gp70 SU protein.
The 5'-protruding ends are digested with Sl-nuclease, and HindIII linkers (5-CCAAGCTTGG-3'; SEQ ID N0: 2) are 30 added. The env gene is cloned as a HindIII fragment in the HindIII site of pLNCX* to form plasmid LNCenvpA. The orient~tion of the HindIII env fragment is such th~t it can be transcribed and expressed from the cytomegalovirus ~; (CNV) promoter.
:; :
WO93/20221 ~33 ~ PCT/US93/02957 Modification of LNCenvpA to LNCenv LNCenvpA is cloned as an XbaI fraament in phagemid pBluescript II SK~ for additional site directed mutagenesis (Figure 3). The env encoding HindIII
5 fragment contains a polyadenylation signal that may interfere with the polyadenylation signal provided by the viral vector. The AAUAAA polyadenylation signal is therefore changed to AAGAAA by site directed mutagenesis with the oligonucleotide 5'-GTTTTCTTTTATC-3' (SEQ ID NO:
10 3). The HindIII site located at the 3' end of the env gene is eliminated by site directed mutagenesis with the oliqonucleotide 5-CAAGCATGGCTTGCC-3' (SEQ ID NO: 4). The env containing retroviral vector is recircularized by XbaI restriction and ligation to form plasmid LNCenv.
15 Molecular clonina of anti-CEA immunoalobulin aenes cDNA encoding the mature variable region domain of ~ ~ anti-CEA heavy chain genes is cloned as an XhoI-SpeI
;~ fragment using the polymerase chain reaction (PCR) and RNA template. RNA is derived from the spleen of mice 20 immunized against purified carcinoembryonic antigen.
~::
Alternat~vely, RNA can be derived from hybridoma cell lines that ~ecrete monoclonal antibodies against CEA, e.g., 1116NS-3d (American Type Culture Collection CRL80~9) or CEA 66-E3 (Wagener, C., et al., 1983, J
2S Immunol 130:2308-2315).
The following PCR primers hybridize to cDNA
encoding the aminoterminal end of mature heavy chain genes (Stratacyte, Inc.). The degenerate primers introduce an XhoI site which is underlined.
W~93/20221 ~ ~ 3 ~ PCT/US93/02~7 5' AGGTGCAGCTGCTCGAGTCGGG 3' (SEQ ID NO: 5) 5' AGGTGCAACTGCTCGAGTCGGG 3' (SEQ ID NO: 6) S~ AGGTGCAGCTGCTCGAGTCTGG 3' (SEQ ID NO: 7) 5' AGGTGCAACTGCTCGAGTCTGG 3' (SEQ ID NO: 8~
5' AGGTCCAGCTGCTCGAGTCTGG 3' ~SEQ ID NO: 9) XhoI
The f~llowing PCR primer hybridizes to immunoglobulin heavy chain mRNA within the region coding for the J-region and introduces SpeI and BstEII sites.
5' CTATTAACTAGTGAC~GTTACCGTGGTCCCTTGGCCCCA 3' (SEQ
ID NO: 10) SpeI BstEII
The amplified anti CEA variable hea~y chain DNA is cloned as an XhoI-SpeI fragment in an ImmunoZ~P H vector (Stratacyte, Inc.) (Mullinax, R.I. et al., 1990, Proc Natl Acad Sci USA 87: 8095-8099). ImmunoZAP H is a modified lambdaZAP vector that has been modified to express in E.coli immunoglobulin variable heavy chain fragments behind a pelB signal sequence. The procadure 20 could similarly be performed by expressing immunoglobulin variable light chain fragments in a packaging cell line.
Identi~ication of hiah affinitY anti-CEA clones Clones expressing high affinity anti-CEA
antibodies axe identified by a f ilter binding assay . The 25 anti-CEA phage library i6 screened by nitrocellulose plaque lifts with ~l25I]bovine serum albumin conjugated to CEA, as previously described (Huse, W.l)., et al., 1989, Science 246:12~5-1281). High and intermediate affinity anti-CEA clones are chosen for further manipulation.
30 Construction of plasmid LNC-immuno~lobulin Two strategies are presented for creating plasmid LNC-immunoglobUlin ( in this example, LNC-an~iCEA, which codes for an anti-CEA immunoglobulin gene). LNC-immunogl o~ul in vectors encode an immunoglobulin peptide W O 93/20221 ~1 ~3~ P~r/US93/02957 fused to an amino-terminal signal se~uence. Some amino acidæ at the amino-terminal end of the mature immunoglobulin peptide have been modified by the PCR
primers used to generate the immunoZAP library.
5 Moreover, the design of the LNC-antiCEA plasmid results in the insertion of an extra amino acid at the amino terminal end. These amino acid changes do not affect antigen binding because 1) ~he amino acid changes are conservative; 2) the affected amino acids are normally 10 variable at those sites; and 3) the affected amino acids occur within the framework region of immunoglobulins`
which has been shown not to participate in antigen binding or conformation of the antibody (Relchman et al.
1988 Nature 332:323-327). It is for these same reasons 15 that cleavage o* the signal seguence from mature peptide will not be affected.
~ Both strategies for creating LNC-immunoglobulin ; ~ rely on the use of plasmid pUC Star-Sig, the construction of which is presented below.
An immunoglobulin signal sequence is cloned into a modified pUCll9 vector to create pUC Star-s~g.as follows (Figure 4). pUCll9 is a phagemid containing a polylinker cloning site. The multiple cloning sites of pUCll9 are replaced with new restriction sites by insertion of the 25 following polylinker into the HindIII and XbaI sites of pUCll9.
Hind~I P~tI XhoI BclI SpeI NotI ClaI Xbal 5'-AGCTTCTGCAGGCTCGAGTGATCAACTAGTGCGGCCGCATCGATT-3' (SEQ
ID N0: 11) 30 3'-AGACGTCCGAGCTCACTAGTTGATCACGCCGGCGTAGCTAAGATC-5'(SEQ
ID N0:12) The modified pUCll9 is called pUC Star-l (Figure 4). The restriction sites may be further separated by small W093/20221 ~ 1 3 3 g 11 rCT/US93/02957 linkers, if adjacent restriction siteæ interfere with one another during digestion.
The signal sequence from an anti-NP immunoglobulin heavy chain gene is isolated from plasmid pcDFL.l (Ucker, S D.S., et al., 1985, J Immnol 135:4204-4214) as a -330bp PstI fragment. The 330bp PstI fragment is subcloned into pUC Star-l to yield plasmid pUC Star-Sig (Figure 4). The PstI fragment is oriented so that the signal sequence can be expressed.
o a. Cons~uç ~ on of L;NC-immunoalobulin through plasmid LNC-Sig. an immunoalobulin expression vector.
LNCX* is converted into a eukaryotic immunoglobu}in expression vector (Figures 4 and 5). An immunoglobulin heavy chain signal sequence and XhoI-SpeI
15 cloning sites are inserted behind the CMV promoter of plasmid LNCX* to allow expression of the PCR amplified im~unoglobulin genes. Conversion of LNCX* is as follows.
The immunoglobulin heavy chain signal sequence is recovered from pUC Star-Sig a8 a HindIII-ClaI restriction 20 fragment ~nd cloned into the HindIII-ClaI sites of LNCX*.
The resulting plasmid, LNC-Sig contains a retroviral vector with the immunoglobulin heavy chain signal sequence under control of the CMV promoter (Figure 5).
An anti-CEA gene from the immunoZAP library is 25 then subcloned into LNC-Sig to form plasmid LNCanti-CEA.
This generates an anti-CEA variable heavy chain gene containing a signal sequence (Figure 6). The anti-CEA
gene is first excised from immunoZAP phage DN~ as a Bluescript SK- phagemid (see lambdaZAP protocols, 30 Stratagene, Inc. La Jolla, CA). The anti-CEA gene is purified as an XhoI-SpeI fragment and l~gated to XhoI-SpeI restricted LNC-S~g. LNC-Stg contains three SpeI
sites. Therefore, to generate plasmid LNCanti-CEA, the ligation mix is transformed into neomycin-sensitive, 35 ampicillin-sensitive E. coli and neomycin-resistant, WO93/20221 ~ 3 3 4 l i PCT/US93/02957 ampieillin-resistant transformants are selected for.
Plasmid LNCanti-CEA is sereened from neomycin-resistant, ampieillin-resistant trans~ormants by using the SpeI-XhoI
anti-CEA restrietion fragment from Bluescript SK-anti-CEA
5 as a probe. The SpeI site is used because of dependenee upon the available sites in the ImmunoZap expression veetor. To simplify eonstruetion of LNCanti-CEA, a unique NotI site ean be introdueed into the ImmunoZap H
expression veetor so that NotI sites ean be used instead lO of SpeI sites.
. Construetion of LNC-immunoalobulin throuah Plasmid pUC Star-Sig An anti-CEA gene from the immunoZAP library is subeloned into plasmid pUC Star-Si~ to form plasmid pUC
15 Star-anti-CEA. This generates an anti-CEA variable heavy ehain gene eontaining a signal sequenee (Figure 12). The anti-CEA gene is exeised from immunoZAP phage DNA as a Blueseript SK-phagemid (~ee lambdaZAP protoeols, Stratagene, Ine., La Jolla, CA). Blueseript SX-anti-CEA
; 20 double ~tranded DNA ~8 prQpared and restrieted with XhoI
and SpeI. The anti-CEA eontaining XhoI-SpeI f~agment is purified by eleetroelution and ligated to Xho-SpeI
restrieted pUC Star-Sig to ereate plasmid pUC Star-antiCEA ~Figure 12).
The antiCEA gene is transferred from pUC Star-anti CEA to LNCX* as a HindIII-ClaI fragment to ereate plasmid LNC-antiCEA (figure 13). The antiCEA-eontaining HindIII-ClaI fragment is purified from pUC Star-antiCEA by eleetroelution. Phosphatase treated, HindIII-ClaI
30 restrieted LNCX* is ligated with the purified HindIII-ClaI antiCEA fragment to generate LNC-antiCEA ~figure 13).
Strateov for generatina targeted viruses The starting materials for generation of targeted 35 viruses are the LNC~nv and LNC-immunoglobulin lin this ~ .
.~'`~, .
W O 93/20221 . X 1 ~ 3 4 1 1 P{~r/US93/02957 example, LNC-antiCEA) plasmids shown in Figure 7.
Figures 8-11 diagram the general principle for the primary generation of targeted viruses. Hybrid i Dunoglobulin-env proteins are generated that target 5 viruses to cells expressing carcinoembryonic antigen.
Since the location of important determinants for envelope protein sorting (S), trimeriza~ion (T), and fusion (F) iæ
; not known with certainty, the i D unoglobulin gene is ligated to progreæsive deletions of the env gene and 10 functional i D unoglobulin-env hybrids are selected for.
Useful Envelo~e Fraoments or Analogs The envelope portion of the fusion protein may consist of any portion of the envelope protein (or any analog thereof) which is sufficient to direct efficient 15 incorporation of the envelope fusion protein into the viral coat ~upon budding of the recombinant virus from a producer cell line). Suc~ fragments or analogs may be determined using the following general selection scheme which generally involves ligation of cell surface 2Q receptor binding domains of ligand genes to progessive deletions of viral envelope genes. The correct combination of ligand and envelope sequences is determined by a selection scheme for the production of biologically active targeted virus. The selection scheme 25 not only produces targeted virus but simplifies the construction of future targeted viruses.
Construction of hvbrid immunoalobulin-env genes in v~txo Plasmid LNCenv contains the coding region for the Mo-MuLV env polyprotein (Figure 8). LNCenv is first 30 linearized by HindIII restriction. A rangQ of deletions extending into the env gene is created by colleoting aliquots of Exonuclease III treatqd DNA over time and removing 5'-processive ends with Sl-nuclease (Guo, I.H., et al., 1983, Methods Enzymol 100:60; and Sambrook, J., 3S et al., 1989, Molecular Clonina, Cold Spring Harbor ` ~
Laboratory Press, Cold Spring Harbor). NotI linkers (5' AGCGGCCGCT 3 ' SEQ ID N0: 13) are ligated onto the blunt end termini and restricted with NotI. This results in a NotI restriction overhang at the 5'-border of every 5 deletion within the env gene. The NotI overhangs at the other end of the molecules are removed by SalI
restriction of the reaction mixture. The reaction mixture is then treated with phosphatase to prevent circularization of the re~ction products.
The reaction mixture is ligated to a SalI-NotI
restriction fragment from LNC-antiCEA that contains the ~` anti-CEA variable heavy chain gene. This creates a pool of functional retroviral vectors encoding an anti-CEA
peptide fused to a series of env deletions.
15 Generation of Dooled virus constructions The total reaction mixture from above is transformed into ampicillin-sensitive E. coli and ampicillin resistance is selected for tFigure 9).
Reoombinants containing functional retroviral vectors are 20 selected for since only they contain the ampicillin resistance gene. Plasmid DNA is prepared from~
transformants grown in liquid culture to create a pool of retroviral vectors containing different immunoglobulin-env fusion genes.
The DNA is tranæfected into the crip2 retroviral packaging cell line (Danos, 0., et al., 1988 , Proc Natl Acad Sci USA 85: 6460-6464). Alternatively, DNA is transfected into a packaging cell line that does not encode wild-type env protein. The transfected packaging 30 cell line synthesizes each of the different hybrid immunoglobulin-env protein~ as well as the wild type env protein (encoded by an env gene contained in the cell line). The transfected packaging cell line secretes a pool of enveloped retroviruses containing the different 35 `retroviral genomes encoding hybrid immunoglobulin-env `` WO93/20221 ~ 1 3 3 ~ PCT/USg3/02957 genes. If the hybrid immunoglobulin-env protein retained all of the neeessary determinants for efficient incorporation into viral envelopes then the hy~rid-env protein ean be incorporated into viral envelopes. Wild 5 type env proteins eneoded for by the packaging eell line are also ineorporated into the viral envelopes. This ereates a virus eontaining both wild type and hybrid env proteins in the viral envelope. This system therefore seleets for immunoglobulin-env hybrids that ean 10 ineorporate their gene produets into the viral envelope.
Virus pools are harvested from media filtered at 0.45~ to remove contaminating G418-resistant paekaging eells.
Seleetion and eharaeterization of targeted virus G418-sensitive target eells are exposed to virus pools by standard proeedures, and G418-resistant eells are seleeted for. The target eells ean be any non-mouse eell line (uninfeetable by wild type No-MuLV) that expresses eareinoembryonie antigen. Examples inelude 20 ATCC COLO 205, a human eell line isolated from the aseites of a patient with eareinoma of the eo~on (A.T.C.C.#CCL 222); LR-73 CEA, a ehinese hamster ovary eell line transfeeted with a mouse eareinoembryonie antigen gene (Benehimol, S. et al., supr~); and HCT48, a 25 human eolon adenoeareinoma eell line (Shi, 2.R., et al., 1883, Can~er Res 43:4045-4049).
G418-resistant eells ean only have arisen from transduetion of the neomyein resistanee gene by targeted virus. This system therefore seleets for reeombinant 30 viruses that have hybrid immunoglobulin-~nv proteins that have retained all the neeessary determinants for viral targeting and fusion.
Reseue of inteorated i~munoalobulin-~nv gene Infeetion by targeted virus results in integration 35 of the hybrid envelope gene that ereated the targeting :
WO93/20221 PCT/US93/02~7 ~1 3 ~ 411 _ 30 ~
protein. The integrated hybrid immunoglobulin-env gene is rescued from the host DNA by polymerase chain reaction (PCR) with the following primers:
PCR 5' Rescue primer:
5 5'-CCAGCCTCCGCGGCCCCAAGCTTCTGCA-3' (SEQ ID NO: 14) HindIII
PCR 3' Rescue primer:
5'-GGTTC~SIaÇaAACTGCTGAGGGC-3' (SEQ ID NO: 15) XbaI
PCR amplification with these primers generates the immnoglobulin-env gene bordered by HindIII and XbaI
sites. The amplified DNA is restricted with HindIII and XbaI to create sticky ends and the DNA is ligated into HindIII-XbaI cut LNCX*. When transfected into crip2 15 packaging cells, this generates a retroviral vector targeted to cells expressing cell surface carcinoembryonic antigen (e.g., colon cancer cells).
The retroviral vector produced in the above selection scheme is targeted to both CEA-expressing human 20 cells (directed by the hybrid envelope protein) and normal mouse cells (directed by the wild type envelope protein) when produced in crip2 packaging cells. To create viruses that infect target cells only, the retroviral vector will first be tested to determine if 25 incorporation of the hybrid envelope protein alone is sufficient to direct virus fusion. This is accomplished by transfecting DNA into a modified packaging cell line that does not encode wild type env.
If fusion functions are found to have been 30 supplied from the wild type envelope protein, targeted viruse~ will be created as follows. A packaging cell line will be created that encodes an env gene containing mutations in the receptor binding domain. When W093~20221 PCT/US93/02g57 `~13~
transfected with the targeted viral vector DNA, targeted viruses expressing both hybrid ligand-env proteins and env proteins with mutated binding sites will be produced.
The viruses will exclusively infect target cells.
5 The taraeted viral vector is a universal vector The viral vector that is constructed by the above procedure is a universal targeted vector (Figure 11).
Targeting to other cells is accomplished by replacing the XhoI-SpeI anti-CEA fragment with any XhoI-SpeI fragment 10 encoding an in-frame immunoglobulin or ligand directed against specific cell surface proteins. For example, an XhoI-SpeI i D unoglobulin-containing fragment from an immunoZAP library can be fused in frame behind a signal sequence and subcloned into LNCX* through the pUC Star-15 Sig plasmid, as outlined above. Substituting a SalI-NotI
fragment from another LNC-immunoglobulin plasmid into the universal vector would create another targeted virus vector.
Other Viral Vectors Any enveloped virus may be used as a vector for the targeted delivery of a therapeutic gene. Particular examples include both DNA and RNA viruses, such as Herpesviridae, e.g., herpes simplex type 1 or 2, Paramyxoviridae, Retroviridae, Hepadnaviridae, 25 Poxviridae, Iridoviridae, Togaviridae, Flaviviridae, Coronaviridae, Rhabodoviridae, Filoviridae, Orthomyxoviridae, Bunyaviridae, or Arenaviridae, or any other, yet unclassified, enveloped virus.
An extensive selection of these viruses is 30 available, e.g., from the American Type Culture Collection.
Taraetina Liaands Any molecule that is capable of directing specific interaction with a target host cell (e.g., by specific 35 recognition of and binding to a host cell surface ~ if ~
W093/20221 2133 ~i 1 i PCT/USg3/02g57 protein) may be used as the targeting ligand portion of the envelope fusion protein. Preferably, such a protein is derived from one member of a ligand:receptor pair.
The targeting ligands are not limited to proteins.
5 Carbohydrate and lipid moieties can be attached to the envelope protein via protein fragments containing consensus ~equences for glycosylation and lipidation.
Immunoglobulin genes can be used as ligands, as shown in the example above. Genes for high affinity lO immunoglobulins are screened from a lambda or bacterial expression library by a filter binding assay with sI] bovive serum albumin conjugated to antigen, as previously described (Huse, et al. Sup~a ) .
Cell surface molecules such as integrins, adhesion l5 molecules or homing receptors can be used as cell-speaific ligands since they are involved in cell-cell interactions via receptors on other cells. Genes encoding these molecules can be identified by the panning method of Seed and Aruffo (Seed. B., et al., 1987, Proc 20 Natl Acad Sci USA 84:3365-3369).
Hormones that bind to specific receptors can be used as targeting ligands as well as viral proteins, such as ~IV envelope protein gpl20, and modifications of naturally occuring ligands.
25 Thera~eutic Genes Therapeutic genes useful in the invention include the following. l) Genes that are therapeutic to cancer cells may include a) antisense oncogenes; b) tumor suppressor genes, such as p53 or the retinoblastoma gene 30 product Rb, c) destructive toxin genes such as a diphtheria toxin gene; d) cytokines æuch as tumor necrosis factor or interferons; or e) any other therapeutic gene. 2) Therapeutic genes targeted to cells that are infected with HIV. Specific examples 35 include antisense DNA complementary to essential genes ` wo g3/2022l ~ 1 3 3 9 1 1 PCT/US93/02~7 for HIV, e.g., polymerase; destructive toxin genes, e.g., diphtheria toxin; and genes that will invoke intracellular immunity, e.g., HIV enhancer sequences that titrate and remove HIV regulatory proteins (Baltimore, 5 D., 1988, Nature 335:395-396). 3) Genes to correct inherited deficiencies. Examples include, but are not limited to, insulin genes delivered specifically to pancreatic beta cells, or the cystic fibrosis transmembrane regulator (CFTR) gene delivered to the 10 appropriate lung cells of cystic fibrosis patients. The expression of targeted genes can be further accomplished through the use of tissue specific enhancers that regulate the transgene.
Therav For any gene therapy described herein, the appropriate recombinant virus, as described above, is administered to a patient in a pharmaceutically-acceptable buffer (e.g., physiological saline). The therapeutic preparation is administered in accordance 20 with the condition to be treated. For example, to treat an HIV-infected individual, the virus is administered by direct injection, e.g., by intravenous, intramuscular, or intraperitoneal injection, at a dosage that provides suitable targeting and lysis of HIV-infected host cells.
25 Alternatively, it may be necessary to administer the targated virus surgically to the appropriate target tissue, or via a catheter, or a videoscope. It may be convenient to administer the therapeutic orally, nasally, or topically, e.g., as a liquid or spray. Again, an 30 appropriate dosage is an amount of therapeutic virus which effects a reduction in the disease.
Targeted virus can also be administered by implanting viral packaging cells into a patient. The cells can be enclosed in a semi-permeable container, 35 e.g., permeable to a virus but not permeable to a ~3~4~
WO93/20221 PCT/USg3/02957 packaging cell. The implanted container may be removable. Alternatively, the container may be hooked up to a patient intravenously, so that virus enters the patient through a needle or through a catheter. In this 5 way the patient receives a continuous dose of viral gene therapy.
Other Embodiments Other embodiments are within the following claims.
For example, replication competent viruses may be lO used in certain cases. In other cases, where replication-deficient viruses are necessary, it may be efficacious to administer modified packaging cells, rather than the targeted virus, to patients. By this method a non-proliferating dose of recombinant virus is 15 delivered to a local area, and then the virus locates the specific target cell. For example, tumor infiltrating lymphocytes (TIL), which surround cancer cells, can be modified to secrete locally high concentrations of cancer cell-targeted virus. Treatment may be repeated as 20 necessary. Immune response against targeted viruses can be overcome with immunosuppressive drugs.
In addition to colon cancer celLs, the ~irus of the invention may be used to target other cancer cells, e.g., ovarian, breast, or lung cancer cells, or cells 25 affected with hereditary diseases such a~ muscular dystrophy, Huntington's disease, or cells with a defect in adenosine deaminase. Herpesviridae viruses may include Herpes simplex type 1 or type 2, Epstein-Barr virus, or Cytomegalovirus. Sendai virus and Vaccinia 30 virus may also be adapted to this method.
~ 1 3 ~ 4 1 1 WO93/20221 . j!. PCT/US93/02~7 BBOUBNCE ~I8TING
BNERAL INFORMATION:
(i) APPLICANT: Alexander T. Young (ii) TITLB OF IN~ENTTON: GENE THERAPY USING
TARGETED VIRAL VECTORS
(~ii) NnMBBR OF 8BQ~ENCE8: 15 (iv) CORRE8POND~NCB ADDRB88:
(A) ADDRE88~B: Fish & Richardson (B) 8TR~T: 225 Franklin Street ~C) CITYs Boston (D) 8TATE: Massachusetts ~B) CO~NTRY: U.S.A.
(F) 8IP: 02110-2804 ~v) COMP~TBR R~ADABLB FORM:
(A) NEDI~ T~PB: 3.5" Diskette, 1.44 Nb (B) CO~P~TDR: IBM PS/2 Model 50Z or 55SX
(C) OPDRATING 8Y8TEM: IBM P.C. DOS (Version 5.00) (D) 8oFT~aRE: WordPerfect (Version 5.1) ~vi) C~RRENT APPLICATION DATA:
~A) APPLICATION N~NB~R:
(B) FILING DATE:
(C) C~A88IFICATION:
) PRIOR APPLIC~TION DATA:
~A) APPLI~ATIO~ N~NBER: 07/862,~95 ~B) FILING DATE: April 3, 1992 (vi~) A~TO~N~Y/AG~NT INFORMATION:
~A) NAME: Paul T. Clark (B) REGI8TRATION N~MBER: 30,162 ~C) REFERBNCE/DOC~ET NUMBER:05140/002002 ;~8) TELBCOMM~NICATION INFORMATION:
~A) TELBP~ON~: (617) 542-5070 ~B) TE$EFAS: (617) 542-8906 (C) TELE~: 200154 t WO 93/20221 ~13 ~ 4 ~ r/us93/o2957 ~2) INFORMATION FOR 8BQ~ENCB IDENTIFICATION N~NBER: 1:
(i) 8BQVBNCB C~ARACTBRI8TIC8:
~A) ~BNGT~: 19 (B) TYPB: nucleic acid ~C) 8TRANDBDNB88: single ~D) TOPO~O~Y: linear ~x~) 8BQ~NCB DB8CRIPTION: SEQ ID NO: 1:
:
~2) I~FORKATION FOR 8BQV~NCB IDBNTIFICaTION NnNBBR: 2:
) 8BQV~NCB CEaRACTERI8TIC8:
:
~A) LBNGT~: 10 (B) TYPB: nucleic acid : ~C) 8TRANDBDNB88: double tD) TOPOLOOY: linear Xi) 8BQV~NCB DB8CRIPTION: SEQ ID NO: 2:
.
2) INFORNATION FOR 8EQVBNCE IDENTIFTCATION N~MBBR: 3:
~) 8BQVBNCB C~ARACTBRI8TIC8:
~A) ~EN~T~: 13 ~B) TYPES nucleic acid ~C) 8TR~NDBDNB88: single tD) TOPOLOGYs linear ~Yi) 8BQ~ ~ CB DB8CRIPTION: SEQ ID NO: 3:
~2) INFORNATION FOR 8EQVBNCJ IDENTIFICATION N~NB~a: 4:
(i) 8BQVENCB C~ARACT~RI8TIC8s ~ ~A) ~EN~T~: 15 :~ (B) ~YP~: nucleic acid (C) 8TRAND~DNB88: single (D) TOP0~04Y: linear .
! --.~
9 1 1 W O ~3/20221 . PC~r/US93/02957 ~i) 8BQUENCE DE8CRIPTION: SEQ ID NO: 4:
(2) INFOR~ATION FOR 8EQ~ENCB IDBNTIFICATION NUNBBR: 5:
~i) 8BQ~ENCE C~RA~TERI8TIC8:
~A) LB~GTH: 22 ~B) TYPE: nucleic acid ~C) 8TRaNDBDNE88: single ~D) TOPOLOGY: linear ~x~) 8BQ~BNCE DE8CRIPTION: SEQ ID NO: 5:
(2) INFOR~ATION FOR 8BQ~BNCB IDBNTIFICATION N~MBBR: 6:
~i) 8BQ~BNCB C~ARACTBRI8TIC8:
~A) L~NG~: 22 (B) TYPE: nucleic acid ~C) 8TRANDgDNE88: single (D) TOPOLOGY: linear ~i) 8BQ~DNCE DE8CRIPTION: SEQ ID NO: ~:
(2) INFORMATION FOR 8EQ~NCE IDENTIFICATION N~NBER: 7:
(i) 8~QUENCE C~ARACTERI8TIC~:
~A) L~NGT~: 22 (B) TYPE: nucleic acid ~C) 8TRANDEDNE88: single ~D) TOPOLO~Y: linear ~xi) BEQ~BNCB DE~CRIPTION: SEQ ID NO: 7:
W O 93/20221 . ~ ~3~ PC~r/US93/02957 ~2) INFO~NATION FOR 8~Q~NC~ IDENTIFICATION NUMBER: 8:
(i) 8EQ~ENCE C~ARACTBRI8TIC8:
~A) LENGTa: 22 (B) TYP~s nucleic acid ~C) 8TRANDEDN~88: single (D) TOPOLOaYs linear (~i) 8BQ~BNCB DE8CRI~TION: SEQ ID NO: 8:
~: AGGTGCAACT GCTCGAGTCT GG 22 ~2) INFOR~ATION FOR 8BQ~ENCB IDENTIFICATION N~MBER: 9:
(1) 8EQ~ENCB C~ARACT8RI8TIC8:
~A) LENGT8: 22 ~B) TYPB: nucleic acid ~C) 8TRANDEDNB88s single ~D) TOPO~O~Y: linear : (xi) 8BQ~BNCB DE8CRIPTION: SEQ ID NO: 9:
: ~ ~2) INFORMATION FOR 8EQ~BNCE IDENTIFICATION NWMBBR: 10:
~:~ (i) 8BQ~BNCB C~ARACTERI8TIC8:
~A) ~ENGT~: 39 ~B) TYPB: nucleic acid ~C) 8TaANDBDNE88s single ~D) TOPOLOCY: linear ~i) 8~QVENCE DE8CRIPTION: SEQ ID NO: 10:
t2) INFORMATION FOR 8EQVgNCE IDENTIFICATION N~MB~R:
11:
~i) 8~QVENC~ C~RACTERI8TIC8:
~A) ~ENGT~: 45 (B) TYP~: nucleic acid (C) 8~RAND~DNE88: double ~: (D) TOPOLOGY: linear :
I` i~13~4~J 1 WO 93/20221 , . PCI~/US93/02957 ~xi) 8gQ~NCE Dg8CRIPTION: SEQ ID NO: 11:
(2) INFORNATION FOR 88Q~BNCg ID8NTIFICATION NVMBER: 12:
(i) 8BQ~BNCB C~ARACTBRI8TIC8:
~A) LB~T~: 4s ~B) TYP8: nucleic acid tC) 8TRANDEDNE88: double tD) TOPOLOGY: linear tx~) 8gQ~NCB DB8CRIPTION: SEQ ID NO: 12:
(2) INFORKaTION FO~ 8BQ~E~CE IDENTIFICATION N~NBER: 13:
i) 8BQ~NC~ C D ACTBRI8TIC8:
~A) LBN~T~: 10 (B) TYPBs nucleic acid tC) 8T~A~D8DN888: double (D) TOPOLO~Ys linear ~: (x~) 8BQ~NCB DB8CRIPTION: SEQ ID NO: 13:
~GCGGCCGCT 10 t2) INFOR~TION FOR 8BQ~NCB IDBNTIFICATION N~MB~R: 14:
(~) 8BQ~BNCB C~ARACTERI8TIC8:
~A) LENGT~: 28 (B) TYPE: nucleic acid ~C) 8TRANDEDNE88: single (D) TOPoLoaY: linear ~i) 8EQ~NCE D~8CRIPTION: SEQ ID NO: 14:
.
WO93/20221 . '1 ~3 ~ PCT/US93/02957 ~2) INFOR~ATION FOR 8~QU~NCE ID~NTIFICATION NUMBDR: l5:
~) 8EQ~ENC~ C~ARACT~RI8TIC8:
~A) LEN~T~: 24 ~B) TYPF: nucleic acid ~) 8TRANDFDNB88: single ~D) TOPO~OGY: linear ~i) 8~Q~ENCE DE8CRIPTION: SEQ ID NO: 15:
(2) INFOR~ATION FOR 8EQ~ENCB IDBNTIFICATION NUNBBR: 5:
~i) 8BQ~ENCE C~RA~TERI8TIC8:
~A) LB~GTH: 22 ~B) TYPE: nucleic acid ~C) 8TRaNDBDNE88: single ~D) TOPOLOGY: linear ~x~) 8BQ~BNCE DE8CRIPTION: SEQ ID NO: 5:
(2) INFOR~ATION FOR 8BQ~BNCB IDBNTIFICATION N~MBBR: 6:
~i) 8BQ~BNCB C~ARACTBRI8TIC8:
~A) L~NG~: 22 (B) TYPE: nucleic acid ~C) 8TRANDgDNE88: single (D) TOPOLOGY: linear ~i) 8BQ~DNCE DE8CRIPTION: SEQ ID NO: ~:
(2) INFORMATION FOR 8EQ~NCE IDENTIFICATION N~NBER: 7:
(i) 8~QUENCE C~ARACTERI8TIC~:
~A) L~NGT~: 22 (B) TYPE: nucleic acid ~C) 8TRANDEDNE88: single ~D) TOPOLO~Y: linear ~xi) BEQ~BNCB DE~CRIPTION: SEQ ID NO: 7:
W O 93/20221 . ~ ~3~ PC~r/US93/02957 ~2) INFO~NATION FOR 8~Q~NC~ IDENTIFICATION NUMBER: 8:
(i) 8EQ~ENCE C~ARACTBRI8TIC8:
~A) LENGTa: 22 (B) TYP~s nucleic acid ~C) 8TRANDEDN~88: single (D) TOPOLOaYs linear (~i) 8BQ~BNCB DE8CRI~TION: SEQ ID NO: 8:
~: AGGTGCAACT GCTCGAGTCT GG 22 ~2) INFOR~ATION FOR 8BQ~ENCB IDENTIFICATION N~MBER: 9:
(1) 8EQ~ENCB C~ARACT8RI8TIC8:
~A) LENGT8: 22 ~B) TYPB: nucleic acid ~C) 8TRANDEDNB88s single ~D) TOPO~O~Y: linear : (xi) 8BQ~BNCB DE8CRIPTION: SEQ ID NO: 9:
: ~ ~2) INFORMATION FOR 8EQ~BNCE IDENTIFICATION NWMBBR: 10:
~:~ (i) 8BQ~BNCB C~ARACTERI8TIC8:
~A) ~ENGT~: 39 ~B) TYPB: nucleic acid ~C) 8TaANDBDNE88s single ~D) TOPOLOCY: linear ~i) 8~QVENCE DE8CRIPTION: SEQ ID NO: 10:
t2) INFORMATION FOR 8EQVgNCE IDENTIFICATION N~MB~R:
11:
~i) 8~QVENC~ C~RACTERI8TIC8:
~A) ~ENGT~: 45 (B) TYP~: nucleic acid (C) 8~RAND~DNE88: double ~: (D) TOPOLOGY: linear :
I` i~13~4~J 1 WO 93/20221 , . PCI~/US93/02957 ~xi) 8gQ~NCE Dg8CRIPTION: SEQ ID NO: 11:
(2) INFORNATION FOR 88Q~BNCg ID8NTIFICATION NVMBER: 12:
(i) 8BQ~BNCB C~ARACTBRI8TIC8:
~A) LB~T~: 4s ~B) TYP8: nucleic acid tC) 8TRANDEDNE88: double tD) TOPOLOGY: linear tx~) 8gQ~NCB DB8CRIPTION: SEQ ID NO: 12:
(2) INFORKaTION FO~ 8BQ~E~CE IDENTIFICATION N~NBER: 13:
i) 8BQ~NC~ C D ACTBRI8TIC8:
~A) LBN~T~: 10 (B) TYPBs nucleic acid tC) 8T~A~D8DN888: double (D) TOPOLO~Ys linear ~: (x~) 8BQ~NCB DB8CRIPTION: SEQ ID NO: 13:
~GCGGCCGCT 10 t2) INFOR~TION FOR 8BQ~NCB IDBNTIFICATION N~MB~R: 14:
(~) 8BQ~BNCB C~ARACTERI8TIC8:
~A) LENGT~: 28 (B) TYPE: nucleic acid ~C) 8TRANDEDNE88: single (D) TOPoLoaY: linear ~i) 8EQ~NCE D~8CRIPTION: SEQ ID NO: 14:
.
WO93/20221 . '1 ~3 ~ PCT/US93/02957 ~2) INFOR~ATION FOR 8~QU~NCE ID~NTIFICATION NUMBDR: l5:
~) 8EQ~ENC~ C~ARACT~RI8TIC8:
~A) LEN~T~: 24 ~B) TYPF: nucleic acid ~) 8TRANDFDNB88: single ~D) TOPO~OGY: linear ~i) 8~Q~ENCE DE8CRIPTION: SEQ ID NO: 15:
Claims (39)
Claims
1. A method for expressing a nucleic acid of interest in a heterologous host cell, said method comprising (a) providing a virus whose genome comprises (i) said nucleic acid of interest and (ii) a hybrid envelope gene, said hybrid gene encoding an envelope fragment joined to a targeting ligand, whereby said envelope fragment does not facilitate recognition or binding of its normal host cell but which does facilitate efficient incorporation of said virus into a mature viral particle and whereby said targeting ligand facilitates targeting and binding of said mature viral particle to the surface of said heterologous host cell, and (b) administering said virus so as to permit viral infection of said heterologous host cell.
2. The method of claim 1, wherein said virus is an envelope virus.
3. The method of claim 2, wherein said envelope virus is a Herpesviridae.
4. The method of claim 2, wherein said envelope virus is a Retroviridae.
5. The method of claim 4, wherein said Retroviridae is a Moloney murine leukemia virus.
6. The method of claim 1, wherein said nucleic acid of interest is DNA.
7. The method of claim 1, wherein said nucleic acid of interest is RNA.
8. The method of claim 1, wherein said heterologous host cell is infectious.
9. The method of claim 1, wherein a portion of said hybrid envelope fragment consists of a receptor binding domain, an oligomerization domain, a transmembrane domain, a virus budding domain, sorting signals, and a signal sequence.
10. The method of claim 9, wherein said envelope fragment further consists of a fusion domain.
11. The method of claim 1, wherein the fusion activity of said envelope fragment is performed by a second protein.
12. The method of claim 1, wherein said administration is by implanting a container enclosing said virus into a patient.
13. The method of claim 12, wherein said virus is inside a packaging cell.
14. A virus, the genome of which encodes a hybrid envelope protein, said hybrid protein comprising an envelope fragment joined in frame to a targeting ligand, whereby said envelope fragment does not facilitate recognition or binding of its normal host cell but which does facilitate efficient incorporation of said hybrid envelope protein into a mature viral particle and whereby said non-viral protein facilitates targeting and binding of said mature viral particle to the surface of a cell not normally infected by said virus.
15. The virus of claim 14, wherein said virus is an envelope virus.
16. The virus of claim 15, wherein said envelope virus is a Herpesviridae.
17. The virus of claim 15, wherein said envelope virus is a Retroviridae.
18. The virus of claim 17, wherein said Retroviridae is a Moloney murine leukemia virus.
19. The virus of claim 14, wherein said nucleic acid of interest is DNA.
20. The virus of claim 14, wherein said nucleic acid of interest is RNA.
21. The virus of claim 14, wherein said heterologous host cell is infectious.
22. The virus of claim 14, wherein a portion of said hybrid envelope protein consists of a receptor binding domain, an oligomerization domain, a transmembrane domain, a virus budding domain, sorting signals, and a signal sequence.
23. The virus of claim 22, wherein said envelope fragment further consists of a fusion domain.
24. The virus of claim 14, wherein the fusion activity of said envelope fragment is performed by a second protein.
25. The virus of claim 14, wherein said administration is by implanting a container enclosing said virus into a patient.
26. The virus of claim 25, wherein said virus is inside a packaging cell.
27. A method for delivering a nucleic acid of interest to a heterologous host cell, said method comprising a) providing a virus whose genome comprises (i) said nucleic acid of interest and (ii) a hybrid envelope gene, said hybrid gene encoding an envelope fragment joined to a targeting ligand, whereby said envelope fragment does not facilitate recognition or binding to its normal host cell but does facilitate efficient incorporation of said virus into a mature viral particle and whereby said targeting ligand facilitates targeting and binding of said mature viral particle to the surface of said heterologous host cell, and b) administering said virus so as to permit viral infection of said cell.
28. The method of claim 27, wherein said virus is an envelope virus.
29. The method of claim 28, wherein said envelope virus is a Herpesviridae.
30. The method of claim 28, wherein said envelope virus is a Retroviridae.
31. The method of claim 30, wherein said Retroviridae is a Moloney murine leukemia virus.
32. The method of claim 27, wherein said nucleic acid of interest is DNA.
33. The method of claim 27, wherein said nucleic acid of interest is an RNA.
34. The method of claim 27, wherein said heterologous host cell is infectious.
35. The method of claim 27, wherein a portion of said hybrid envelope fragment consists of a receptor binding domain, an oligomerization domain, a transmembrane domain, a virus budding domain, sorting signals, and a signal sequence.
36. The method of claim 35, wherein said envelope fragment further consists of a fusion domain.
37. The method of claim 27, wherein said the fusion activity of said envelope fragment is performed by a second protein.
38. The method of claim 27, wherein said administration is by implanting a container enclosing said virus into a patient.
39. The method of claim 38, wherein said virus is inside a packaging cell.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86279592A | 1992-04-03 | 1992-04-03 | |
US862,795 | 1992-04-03 | ||
US4074893A | 1993-03-29 | 1993-03-29 | |
US08/040,748 | 1993-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2133411A1 true CA2133411A1 (en) | 1993-10-14 |
Family
ID=26717389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002133411A Abandoned CA2133411A1 (en) | 1992-04-03 | 1993-03-31 | Gene therapy using targeted viral vectors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0633943A4 (en) |
JP (1) | JPH07505773A (en) |
AU (1) | AU3940293A (en) |
CA (1) | CA2133411A1 (en) |
WO (1) | WO1993020221A1 (en) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643756A (en) * | 1992-08-28 | 1997-07-01 | The Public Health Research Institute Of The City Of New York, Inc. | Fusion glycoproteins |
CA2145063A1 (en) | 1992-09-22 | 1994-03-31 | Cambridge Genetics Limited | Recombinant viruses displaying a nonviral polypeptide on their external surface |
JP3533219B2 (en) * | 1992-11-09 | 2004-05-31 | アメリカ合衆国 | Targeting vector particles |
DE69520496T2 (en) * | 1994-05-13 | 2001-07-12 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | METHOD AND COMPOSITIONS AS VEHICLES FOR TARGETED INTRODUCTION OF GENES |
US5753499A (en) * | 1994-12-23 | 1998-05-19 | New York University | Viral vector complexes having adapters of predefined valence |
JP2001519647A (en) * | 1995-12-28 | 2001-10-23 | カイロン コーポレイション | Receptor-specific chimeric virus surface polypeptide for virus and particle uptake and internalization into target cells |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US7026116B1 (en) | 1996-04-04 | 2006-04-11 | Bio-Rad Laboratories, Inc. | Polymorphisms in the region of the human hemochromatosis gene |
US6140305A (en) | 1996-04-04 | 2000-10-31 | Bio-Rad Laboratories, Inc. | Hereditary hemochromatosis gene products |
US6849399B1 (en) | 1996-05-23 | 2005-02-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for diagnosis and treatment of iron misregulation diseases |
US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
WO1998021228A1 (en) | 1996-11-15 | 1998-05-22 | Canji, Inc. | Tissue specific expression of retinoblastoma protein |
US6074850A (en) * | 1996-11-15 | 2000-06-13 | Canji, Inc. | Retinoblastoma fusion polypeptides |
US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
ATE388720T1 (en) | 1997-04-10 | 2008-03-15 | Univ Southern California | MODIFIED PROTEINS BONDING TO EXTRACELLULAR MATRIX COMPONENTS |
US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
AU766675B2 (en) | 1998-03-30 | 2003-10-23 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
PL202844B1 (en) | 1998-04-07 | 2009-07-31 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis |
US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
DE19904800C1 (en) | 1999-02-05 | 2001-02-08 | Eberhard Hildt | Particles for gene therapy |
JP2000279178A (en) * | 1999-02-24 | 2000-10-10 | Japan Found Cancer Res | Virus vector |
AU3501700A (en) | 1999-02-26 | 2000-09-14 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US6759393B1 (en) | 1999-04-12 | 2004-07-06 | Pfizer Inc. | Growth hormone and growth hormone releasing hormone compositions |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
AU5011200A (en) | 1999-05-14 | 2000-12-05 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
KR20020056923A (en) | 1999-11-18 | 2002-07-10 | 코르바스 인터내셔날, 인코포레이티드 | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
EP2210948A3 (en) | 1999-12-10 | 2010-10-06 | Life Technologies Corporation | Use of multiple recombination sites with unique specificity in recombinational cloning |
AU2002219944B2 (en) | 2000-11-28 | 2008-02-21 | Medimmune, Llc | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
US6887472B2 (en) | 2000-08-30 | 2005-05-03 | Pfizer Inc. | Anti-IgE vaccines |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
JP2004536579A (en) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Vascular endothelial growth factor 2 |
FI116851B (en) | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Expression vector, its uses and process for its preparation and products containing it |
JP2003047482A (en) | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY |
MXPA03010747A (en) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to trail receptors. |
US7449562B2 (en) | 2001-06-29 | 2008-11-11 | Novartis Ag | PERV screening method and use thereof |
EP1451214A2 (en) | 2001-11-26 | 2004-09-01 | Hybrigenics | Protein-protein interactions in human immunodeficiency virus |
EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | Recombinant anti-interleukin-9 antibodies |
TR200500108T2 (en) * | 2002-07-18 | 2005-04-21 | Helix Biopharma Corp. | Use of Urease for Inhibiting Cancer Cell Development |
ATE536188T1 (en) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
EP2218779A1 (en) | 2002-12-16 | 2010-08-18 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
ES2897506T3 (en) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identification and modification of antibodies with variant Fc regions and methods of using them |
US8021833B2 (en) | 2003-02-12 | 2011-09-20 | Functional Genetics, Inc. | Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
ES2335005T5 (en) | 2003-03-05 | 2013-04-17 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process to prepare it, uses and pharmaceutical compositions that comprise it |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
EP1639086A4 (en) | 2003-06-13 | 2007-07-11 | Univ New Jersey Med | Rna interferases and methods of use thereof |
US7393534B2 (en) | 2003-07-15 | 2008-07-01 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases |
EP1668111A4 (en) | 2003-08-08 | 2008-07-02 | Genenews Inc | Osteoarthritis biomarkers and uses thereof |
US20050048617A1 (en) | 2003-08-18 | 2005-03-03 | Medimmune, Inc. | Humanization of antibodies |
WO2005032572A2 (en) | 2003-10-03 | 2005-04-14 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
US20050227251A1 (en) | 2003-10-23 | 2005-10-13 | Robert Darnell | Method of purifying RNA binding protein-RNA complexes |
US7962316B2 (en) | 2003-10-27 | 2011-06-14 | Merck Sharp & Dohme Corp. | Method of designing siRNAs for gene silencing |
HUE049161T2 (en) | 2003-12-23 | 2020-09-28 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
EP1786463A4 (en) | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | Antibodies against nogo receptor |
CN101426489A (en) | 2004-04-16 | 2009-05-06 | 曹义海 | Compositions and methods for inhibiting angiogenesis |
CA2565450C (en) | 2004-05-07 | 2018-03-06 | Gyorgy Petrovics | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer |
US8415298B2 (en) | 2004-06-21 | 2013-04-09 | The Board Of Trustees Of The Leland Stanford Junior University Of Stanford | Administration of FGF2 for treamtent of anxiety |
CA2572467A1 (en) * | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
CA2574709A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
EP2422811A2 (en) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
US20090022708A1 (en) | 2004-12-22 | 2009-01-22 | Lobie Peter E | Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
EP2520669A3 (en) | 2005-02-07 | 2013-02-27 | GeneNews Inc. | Mild osteoathritis biomarkers and uses thereof |
EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
ES2526811T3 (en) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identification and modification of antibodies with Fc regions variants and methods of use of these |
EP2319941A3 (en) | 2005-10-21 | 2011-08-17 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
WO2007056227A2 (en) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
EP1951908B1 (en) | 2005-11-12 | 2013-08-07 | The Board of Trustees of The Leland Stanford Junior University | Fgf2-related methods for diagnosing and treating depression |
BRPI0710213A2 (en) | 2006-03-30 | 2011-04-12 | Ptc Therapeutics Inc | methods for producing an effective amount of a functional transleeding protein encoded by a nucleic acid sequence comprising a nonsense mutation and for treating, controlling and / or preventing disease |
PL2029173T3 (en) | 2006-06-26 | 2017-04-28 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
EA021255B1 (en) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Antagonistic human light-specific human monoclonal antibodies |
CA3018520C (en) | 2006-10-10 | 2022-05-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations |
EP2064335A4 (en) | 2006-10-16 | 2011-03-30 | Medimmune Llc | Molecules with reduced half-lives, compositions and uses thereof |
EP2094282A4 (en) | 2006-11-15 | 2010-05-05 | Functional Genetics Inc | Anti-tsg101 antibodies and their uses for treatment of viral infections |
WO2008076960A2 (en) | 2006-12-18 | 2008-06-26 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US20110206673A1 (en) | 2007-06-27 | 2011-08-25 | Liu Dongxu | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
NZ583605A (en) | 2007-08-29 | 2012-10-26 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
CN107236044B (en) | 2008-04-02 | 2021-07-02 | 宏观基因有限公司 | HER 2/neu-specific antibodies and methods of use thereof |
US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
ES2675730T3 (en) | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Antibodies with altered FcRn binding and methods of use thereof |
RU2478648C2 (en) | 2008-09-07 | 2013-04-10 | Гликонекс Инк. | Anti-extended type i glycosphingolipid antibody, its derivatives and use thereof |
RU2744176C2 (en) | 2008-12-19 | 2021-03-03 | Макродженикс, Инк. | Covalent diabodies and use thereof |
US20110312872A1 (en) | 2008-12-22 | 2011-12-22 | Universität Regensburg | Norrin in the treatment of diseases associated with an increased tgf-beta activity |
CN102459576B (en) | 2009-04-27 | 2015-04-01 | 渥太华医院研究所 | Compositions and methods for modulating stem cells and uses thereof |
WO2010141329A1 (en) | 2009-06-01 | 2010-12-09 | Medimmune, Llc | Molecules with extended half-lives and uses thereof |
BR112012003064B8 (en) | 2009-08-13 | 2021-05-25 | Crucell Holland Bv | antibody or antigen-binding fragment thereof, combination comprising them, method of detecting rsv infection, nucleic acid molecules, and method of producing an antibody or antigen-binding fragment thereof |
WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
WO2011046457A1 (en) | 2009-10-16 | 2011-04-21 | Auckland Uniservices Limited | Anti-neoplastic uses of artemin antagonists |
CA2779496A1 (en) | 2009-11-02 | 2011-05-05 | The Administrators Of The Tulane Educational Fund | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
EP2496604B1 (en) | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
CN102892778B (en) | 2010-02-19 | 2018-06-08 | 列日大学 | For treating polynucleotides, albumen and the transgenic animals of the disease of influenza A virus induction, the modified Mx albumen of coding |
JP5744196B2 (en) | 2010-07-09 | 2015-07-08 | クルセル ホランド ベー ヴェー | Anti-human respiratory polynuclear virus (RSV) antibodies and methods of use |
WO2012013249A1 (en) | 2010-07-30 | 2012-02-02 | Université de Liège | Dentin matrix protein 1 (dmp1) for use in pharmaceutical compositions |
CN103154025B (en) | 2010-08-02 | 2015-07-01 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
US10130687B2 (en) | 2011-01-05 | 2018-11-20 | Rhode Island Hospital | Compositions and methods for the treatment of orthopedic disease or injury |
JP6145088B2 (en) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | Deimmunized serum binding domain and its use to extend serum half-life |
US9732130B2 (en) | 2011-09-16 | 2017-08-15 | Ottawa Hospital Research Institute | WNT7A compositions and method of using the same |
US9873722B2 (en) | 2011-09-16 | 2018-01-23 | Fate Therapeutics, Inc. | Wnt compositions and therapeutic uses of such compositions |
EP2814842B1 (en) | 2012-02-15 | 2018-08-22 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
EP3196214B1 (en) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
EP2866821B1 (en) | 2012-07-02 | 2018-11-14 | Medizinische Universität Wien | Complement split product c4d for the treatment of inflammatory conditions |
US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
WO2014120975A1 (en) | 2013-02-01 | 2014-08-07 | California Institute Of Technology | Antibody-mediated immunocontraception |
WO2015127351A1 (en) | 2014-02-24 | 2015-08-27 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
US9458464B2 (en) | 2014-06-23 | 2016-10-04 | The Johns Hopkins University | Treatment of neuropathic pain |
KR102465120B1 (en) | 2014-07-17 | 2022-11-10 | 노보 노르디스크 에이/에스 | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
CN107249605A (en) | 2014-11-17 | 2017-10-13 | 阿迪塞特生物股份有限公司 | The gamma delta T cells of engineering |
US10729790B2 (en) | 2015-05-26 | 2020-08-04 | Salk Institute For Biological Studies | Motor neuron-specific expression vectors |
US9920100B2 (en) | 2015-06-05 | 2018-03-20 | The Chinese University Of Hong Kong | Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy |
US20190145961A1 (en) | 2016-04-20 | 2019-05-16 | Washington University | Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity |
IL301527A (en) | 2016-05-12 | 2023-05-01 | Adicet Bio Inc | METHODS FOR SELECTIVE EXPANSION OF ɣδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF |
MX2020005005A (en) | 2017-11-15 | 2020-08-27 | Adicet Bio Inc | Methods for selective expansion of î´3 î³î´ t-cell populations and compositions thereof. |
DE102017127984B4 (en) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Method for the propagation and activation of γδ T cells |
KR20200139219A (en) | 2018-04-02 | 2020-12-11 | 브리스톨-마이어스 스큅 컴퍼니 | Anti-TREM-1 antibodies and uses thereof |
US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
CA3126896A1 (en) | 2018-12-03 | 2020-06-11 | Adicet Bio Inc. | Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof |
CR20210669A (en) | 2019-05-27 | 2022-05-05 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
US20230201315A1 (en) | 2020-01-03 | 2023-06-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Tnap locally administered for promoting periodontal health |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
DE102020106710A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
DE102021100038A1 (en) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | MODIFIED CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
TW202241938A (en) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Cd8 polypeptides, compositions, and methods of using thereof |
KR20230135586A (en) | 2021-01-24 | 2023-09-25 | 마이클 데이비드 포레스트 | ATP synthase inhibitors - cosmetic and therapeutic uses |
WO2022240824A1 (en) | 2021-05-13 | 2022-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for treating sickle cell diseases |
WO2023004332A2 (en) | 2021-07-19 | 2023-01-26 | New York University | Adeno-associated viral vector compositions and methods of promoting muscle regeneration |
WO2023064255A2 (en) | 2021-10-15 | 2023-04-20 | The Regents Of The University Of California | Diagnosis and treatment of anti-pf4 induced thrombocytopenia |
WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
AR128222A1 (en) | 2022-01-07 | 2024-04-10 | Johnson & Johnson Entpr Innovation Inc | IL-1b BINDING PROTEIN MATERIALS AND METHODS |
WO2023146807A1 (en) | 2022-01-25 | 2023-08-03 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
WO2023200897A1 (en) | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Use of viral il-6 in cancer therapy |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0466815A4 (en) * | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
EP0845537A1 (en) * | 1989-08-18 | 1998-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
JPH06500923A (en) * | 1990-09-21 | 1994-01-27 | カイロン コーポレイション | packaging cells |
CA2104396C (en) * | 1991-02-19 | 2000-10-10 | Jiing-Kuan Yee | Viral particles having altered host range |
WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
WO1993005147A1 (en) * | 1991-08-30 | 1993-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Defective interfering hiv particles with chimeric cd4-env |
AU3434393A (en) * | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
-
1993
- 1993-03-31 CA CA002133411A patent/CA2133411A1/en not_active Abandoned
- 1993-03-31 AU AU39402/93A patent/AU3940293A/en not_active Abandoned
- 1993-03-31 JP JP5517626A patent/JPH07505773A/en active Pending
- 1993-03-31 EP EP93908659A patent/EP0633943A4/en not_active Withdrawn
- 1993-03-31 WO PCT/US1993/002957 patent/WO1993020221A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1993020221A1 (en) | 1993-10-14 |
EP0633943A1 (en) | 1995-01-18 |
JPH07505773A (en) | 1995-06-29 |
AU3940293A (en) | 1993-11-08 |
EP0633943A4 (en) | 1997-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2133411A1 (en) | Gene therapy using targeted viral vectors | |
AU723715B2 (en) | Adenoviral mediated gene transfer in adipocytes and related implants | |
Salmons et al. | Targeting of retroviral vectors for gene therapy | |
DE69534792T2 (en) | ADMINISTRATION OF COMPLETE FACTOR VIII WITH THE HELP OF A RETROVIRAL SYSTEM | |
Frecha et al. | Strategies for targeting lentiviral vectors | |
JPH10500287A (en) | Non-crossing retroviral vector | |
US20060140920A1 (en) | Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain | |
AU753809B2 (en) | Recombinant adenoviral vectors comprising a splicing sequence | |
CA2198462A1 (en) | Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle | |
JP3908274B2 (en) | Vector having a therapeutic gene encoding an antimicrobial peptide for gene therapy | |
Rowland et al. | Potential gene therapy strategies in the treatment of cardiovascular disease | |
DE69527544T2 (en) | COMBINATION VECTORS FOR DISCHARGING GENERAL MATERIAL | |
US5736360A (en) | Endothelial cell tropic compositions and methods of making and using the same | |
EP0880594B1 (en) | Retroviral vector and its use in gene therapy | |
WO1999026480A1 (en) | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases | |
KR20040097249A (en) | Drugs Comprising Protein Forming Hollow Nanoparticles and Therapeutic Substance to Be Transferred into Cells Fused Therewith | |
Dickler et al. | Gene therapy in the treatment of disease | |
AU780164B2 (en) | Novel implant and novel vector for the treatment of acquired diseases | |
AU738995B2 (en) | Novel implant and novel vector for the treatment of acquired diseases | |
Rüger | Methoden der Genübertragung | |
DE19858441C2 (en) | FV vectors for the expression of foreign genes in mammals and their use | |
JPH10512276A (en) | Delivery of therapeutics by gene therapy | |
JPH11285394A (en) | Adenovirus transfer vector for transporting gene with dna sequence | |
Rüger et al. | Methoden der Genübertragung | |
Wivel | Gene therapy: historical overview and public oversight |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |